<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006681.pub4" GROUP_ID="PVD" ID="144506110816224087" MERGED_FROM="" MODIFIED="2017-08-07 15:45:34 +0100" MODIFIED_BY="Marlene Stewart" REVIEW_NO="171" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2017-08-07 15:45:34 +0100" MODIFIED_BY="Marlene Stewart">
<TITLE MODIFIED="2017-07-28 09:50:01 +0100" MODIFIED_BY="[Empty name]">Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization</TITLE>
<CONTACT MODIFIED="2017-08-07 15:45:34 +0100" MODIFIED_BY="Marlene Stewart"><PERSON ID="z1701101241216576785810347523595" ROLE="AUTHOR"><FIRST_NAME>Aniek</FIRST_NAME><MIDDLE_INITIALS>AG</MIDDLE_INITIALS><LAST_NAME>Zee</LAST_NAME><EMAIL_1>aniek_zee@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>VieCuri Medical Centre of Northern Limburg</ORGANISATION><CITY>Venlo</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-08-07 15:45:34 +0100" MODIFIED_BY="Marlene Stewart"><PERSON ID="z1701101241216576785810347523595" ROLE="AUTHOR"><FIRST_NAME>Aniek</FIRST_NAME><MIDDLE_INITIALS>AG</MIDDLE_INITIALS><LAST_NAME>Zee</LAST_NAME><EMAIL_1>aniek_zee@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>VieCuri Medical Centre of Northern Limburg</ORGANISATION><CITY>Venlo</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="z1605271020101304531021612159223" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Kelly</FIRST_NAME><LAST_NAME>van Lieshout</LAST_NAME><POSITION>Emergency Physician</POSITION><EMAIL_1>kevanlieshout@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Emergency Department</DEPARTMENT><ORGANISATION>Deventer Ziekenhuis</ORGANISATION><CITY>Deventer</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="z1605271022073342205964786988675" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Maaike</FIRST_NAME><LAST_NAME>van der Heide</LAST_NAME><POSITION>Emergency Medicine Resident</POSITION><EMAIL_1>maaike_van_der_heide@hotmail.com</EMAIL_1><ADDRESS><ORGANISATION>VieCuri Medical Centre of Northern Limburg</ORGANISATION><CITY>Venlo</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="z1301231109503923937230841896416" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Loes</FIRST_NAME><LAST_NAME>Janssen</LAST_NAME><EMAIL_1>loesjanssen@viecuri.nl</EMAIL_1><URL>www.viecuri.nl</URL><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT><ORGANISATION>VieCuri Medical Centre of Northern Limburg</ORGANISATION><ADDRESS_1>Tegelseweg 210</ADDRESS_1><CITY>Venlo</CITY><ZIP>5912 BL</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 77 320 59 62</PHONE_1></ADDRESS></PERSON><PERSON ID="C81DEC4B82E26AA2005DA36465EE1598" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Heinrich</FIRST_NAME><MIDDLE_INITIALS>MJ</MIDDLE_INITIALS><LAST_NAME>Janzing</LAST_NAME><POSITION>Consultant surgeon</POSITION><EMAIL_1>hjanzing@viecuri.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>VieCuri Medical Centre of Northern Limburg</ORGANISATION><ADDRESS_1>Tegelseweg 210</ADDRESS_1><CITY>Venlo</CITY><ZIP>5912 BL</ZIP><REGION>Limburg</REGION><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 773 205309</PHONE_1><FAX_1>+31 773 205319</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-08-07 13:34:22 +0100" MODIFIED_BY="Marlene Stewart">
<UP_TO_DATE>
<DATE DAY="19" MONTH="4" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="4" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="4" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-08-07 15:42:39 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-07 15:42:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="8" YEAR="2017"/>
<DESCRIPTION>
<P>In abstract incorrect I² for PE displayed and P values relating to heterogeneity incorrectly displayed as P values of effect estimate; text revised</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-08-07 14:03:52 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-08-07 14:03:52 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>Searches were rerun. Two new studies were included. Nine additional studies were excluded. New authors joined review team. 'Risk of bias' and 'Summary of findings' tables added. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-08-07 14:03:48 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>Searches were rerun. Two new studies were included. Nine additional studies were excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-07-31 09:07:09 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Searches were rerun. No new studies were included. Five additional studies were excluded. One ongoing study added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-05-31 13:20:50 +0100" MODIFIED_BY="Cathryn  Broderick">
<DATE DAY="4" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Searches were rerun. No new studies were included. Five additional studies were excluded. One ongoing study added. Minor edits made. One new author joined review team. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-03 10:13:56 +0100" MODIFIED_BY="Karen Welch">
<DATE DAY="14" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Link to anticoagulant feedback added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-14 11:34:35 +0000" MODIFIED_BY="Marlene Stewart">
<DATE DAY="10" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Amendment to Plain language summary at the request of the authors. Amendments to contact details of two authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-14 11:34:32 +0000" MODIFIED_BY="Marlene Stewart">
<DATE DAY="18" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-07-28 10:18:19 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2017-07-28 10:18:19 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-05-31 13:58:21 +0100" MODIFIED_BY="Cathryn  Broderick">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The Cochrane Vascular editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2017-07-28 10:18:19 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This project was supported by the NIHR, via Cochrane Incentive Award funding (16/72/06) to Cochrane Vascular. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-08-07 15:40:56 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-07-28 09:55:03 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2017-07-28 09:51:02 +0100" MODIFIED_BY="[Empty name]">Low molecular weight heparin for prevention of venous thromboembolism in adults with lower-limb immobilization in an outpatient setting</TITLE>
<SUMMARY_BODY MODIFIED="2017-07-28 09:55:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Venous thromboembolism is a condition where a blood clot forms in the deep veins (DVT), most commonly of the leg. The concern is that it can travel up to block the arteries in the lungs (pulmonary embolism). In adult patients, immobilization of the lower limb with a plaster cast or brace is a risk factor for DVT and pulmonary embolism. To prevent this complication, preventive treatment with anticoagulants (medication that thins the blood) is often used, most commonly, low molecular weight heparin (LMWH). However, there is no agreement on this in existing national guidelines. Therefore, we searched the literature for trials on this topic, in order to assess the evidence.</P>
<P>
<B>Study characteristics and key results</B>
</P>
<P>We included eight studies in this review (current until April 2017). The studies included a total of 3680 participants. Participants received either LMWH subcutaneously once daily, or no preventive treatment or placebo. New cases of DVT ranged from 4.3% to 40% in the control groups and ranged from 0% to 37% in the LMWH groups. The risk of DVT was lower in participants who received LMWH. Further analysis also showed a reduction in the occurrence of DVT when the use of LMWH was compared to no treatment or placebo in the following groups of participants: patients with below-knee casts, conservatively treated patients (patients not operated), operated patients, patients with fractures, patients with soft-tissue injuries, patients with above-knee thrombosis, and patients with below-knee thrombosis. No clear differences were found between the LMWH and control groups for pulmonary embolism. The studies showed less symptomatic venous thromboembolism in the LMWH groups compared with the control groups. No cases of death due to pulmonary embolism were reported. One study reported one death in the control group.</P>
<P>There were few reported adverse effects in the treated patients. The main adverse events reported were cases of minor bleeding such as nose bleeds, blood in urine and dark stool.</P>
<P>
<B>Quality of evidence and conclusion</B>
</P>
<P>The use of LMWH in adult patients reduced DVT when immobilization of the lower limb was required, compared with no prevention or placebo. The quality of the evidence was downgraded to moderate due to risks of bias in some trials, such as lack of blinding of participants, or unclear reasons for excluding participants from the analyses. Low-quality evidence showed no clear differences in pulmonary embolism between LMWH and the control groups, but fewer symptomatic venous thromboemboli in the LMWH groups. The quality of evidence was downgraded due to methodological issues and imprecision of the results.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-08-07 15:40:56 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-07-28 09:50:09 +0100" MODIFIED_BY="[Empty name]">
<P>Immobilization of the lower limb is a risk factor for venous thromboembolism (VTE). Low molecular weight heparins (LMWHs) are anticoagulants, which might be used in adult patients with lower-limb immobilization to prevent deep venous thrombosis (DVT) and its complications. This is an update of the review first published in 2008.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-07-28 09:50:09 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of low molecular weight heparin for the prevention of venous thromboembolism in patients with lower-limb immobilization in an ambulatory setting.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-07-28 09:50:12 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, the Cochrane Vascular Information Specialist searched the Specialised Register, CENTRAL, and three trials registers (April 2017). </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-07-28 09:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that described thromboprophylaxis by means of LMWH compared with no prophylaxis or placebo in adult patients with lower-limb immobilization. Immobilization was by means of a plaster cast or brace.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-07-28 09:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently selected trials, assessed risk of bias and extracted data. The review authors contacted the trial authors for additional information if required. Statistical analysis was carried out using Review Manager 5.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-08-07 15:40:56 +0100" MODIFIED_BY="[Empty name]">
<P>We included eight RCTs that fulfilled our criteria, with a total of 3680 participants. The quality of evidence, according GRADE, varied by outcome and ranged from low to moderate. We found an incidence of DVT ranging from 4.3% to 40% in patients who had a leg injury that had been immobilized in a plaster cast or a brace for at least one week, and who received no prophylaxis, or placebo. This number was significantly lower in patients who received daily subcutaneous injections of LMWH during immobilization, with event rates ranging from 0% to 37% (odds ratio (OR) 0.45, 95% confidence interval (CI) 0.33 to 0.61; with minimal evidence of heterogeneity: I² = 26%, P = 0.23; seven studies; 1676 participants, moderate-quality evidence). Comparable results were seen in the following groups of participants: patients with below-knee casts, conservatively treated patients (non-operated patients), operated patients, patients with fractures, patients with soft-tissue injuries, and patients with distal or proximal thrombosis. No clear differences were found between the LMWH and control groups for pulmonary embolism (OR 0.50, 95% CI 0.17 to 1.47; with no evidence of heterogeneity: I² = 0%, P = 0.56; five studies, 2517 participants; low-quality evidence). The studies also showed less symptomatic VTE in the LMWH groups compared with the control groups (OR 0.40, 95% CI 0.21 to 0.76; with minimal evidence of heterogeneity: I² = 16%, P = 0.31; six studies; 2924 participants; low-quality evidence). One death was reported in the included studies, but no deaths due to pulmonary embolism were reported. Complications of major adverse events were rare, with minor bleeding the main adverse events reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-07-28 09:51:01 +0100" MODIFIED_BY="[Empty name]">
<P>Moderate-quality evidence showed that the use of LMWH in outpatients reduced DVT when immobilization of the lower limb was required, when compared with no prophylaxis or placebo. The quality of the evidence was reduced to moderate because of risk of selection and attrition bias in the included studies. Low-quality evidence showed no clear differences in PE between the LMWH and control groups, but less symptomatic VTE in the LMWH groups. The quality of the evidence was downgraded due to risk of bias and imprecision.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-07-28 10:13:52 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-07-28 10:13:01 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2017-07-28 09:56:00 +0100" MODIFIED_BY="[Empty name]">
<P>Lower-limb immobilization is associated with deep venous thrombosis (DVT) and pulmonary embolism (PE). Predisposing risk factors for venous thromboembolism (VTE) can be divided into individual patient factors, trauma, or surgery-related factors. Patient-related factors include: obesity, thrombophilia (a hereditary or acquired predisposition to thrombosis), a previous thrombosis, age over 40 years, or cardiac or respiratory failure (<LINK REF="REF-Anderson-2003" TYPE="REFERENCE">Anderson 2003</LINK>; <LINK REF="REF-Clagett-1995" TYPE="REFERENCE">Clagett 1995</LINK>; <LINK REF="STD-Zagrodnick-1990" TYPE="STUDY">Zagrodnick 1990</LINK>). Immobilization is considered a significant risk factor for the development of DVT and PE (<LINK REF="STD-Knudson-1996" TYPE="STUDY">Knudson 1996</LINK>; <LINK REF="STD-Kudsk-1989" TYPE="STUDY">Kudsk 1989</LINK>; <LINK REF="REF-Kujath-1991" TYPE="REFERENCE">Kujath 1991</LINK>). Other factors associated with an increased risk of VTE include: blood transfusion, surgery, fracture of the pelvis, femur, or tibia, spinal cord injury, head injury, shock on hospital admission, venous injury, more than three days on ventilation, the time from injury to operation, and operation time (<LINK REF="STD-Abelseth-1996" TYPE="STUDY">Abelseth 1996</LINK>; <LINK REF="STD-Knudson-2004" TYPE="STUDY">Knudson 2004</LINK>).</P>
<P>In a group of 102 patients with lower-limb fractures, Abelseth found a rate of DVT of 28% (<LINK REF="STD-Abelseth-1996" TYPE="STUDY">Abelseth 1996</LINK>). All patients underwent surgery and were mobilized without the use of a plaster cast. Proximal fractures were associated with a higher risk of DVT compared with more distal fractures (<LINK REF="STD-Abelseth-1996" TYPE="STUDY">Abelseth 1996</LINK>). Other reported incidences of venographically-proven DVT in patients with lower-limb fractures range from 27% to 78% (<LINK REF="STD-Breyer-1984" TYPE="STUDY">Breyer 1984</LINK>; <LINK REF="STD-Geerts-1994" TYPE="STUDY">Geerts 1994</LINK>; <LINK REF="STD-Hjelmstedt-1968" TYPE="STUDY">Hjelmstedt 1968</LINK>; <LINK REF="STD-Kudsk-1989" TYPE="STUDY">Kudsk 1989</LINK>; <LINK REF="STD-Spieler-1972" TYPE="STUDY">Spieler 1972</LINK>). The percentages in hospitalized patients are generally higher than in outpatients. In outpatients immobilized in plaster casts without LMWH, the incidence of DVT on ultrasonography ranges from 4.5% to 16.5% (<LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Reilmann-1993" TYPE="STUDY">Reilmann 1993</LINK>; <LINK REF="STD-Zagrodnick-1990" TYPE="STUDY">Zagrodnick 1990</LINK>). The incidence of PE in trauma patients with DVT without prophylaxis is 4.3%, with a high mortality rate (20% to 23.3%). In patients with DVT receiving thromboprophylaxis, this incidence can be lowered to 0.3% to 2.0% (<LINK REF="REF-Hill-2002" TYPE="REFERENCE">Hill 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-07-28 10:13:01 +0100" MODIFIED_BY="[Empty name]">
<P>The primary goal of administering thromboprophylaxis is to prevent PE and DVT and their sequelae. Oral anticoagulants, unfractionated heparin (UFH) and LMWH, have been studied as treatment options for this indication. In clinical guidelines, the recommendations for preventing venous thrombosis in patients with isolated lower-limb injuries distal to the knee are sparse. The Italian Intersociety Consensus Statement states that most patients in orthopedic and traumatological fields, other than knee and hip replacements, should be considered for thromboprophylaxis after individual assessment of haemorrhagic risk (<LINK REF="REF-Della-Rocca-2013" TYPE="REFERENCE">Della Rocca 2013</LINK>). Guidelines in Emergency Medicine Network in the United Kingdom (GEMNet) only advises the use of thromboprophylaxis in patients with rigid cast immobilization and a permanent risk factor for VTE (<LINK REF="REF-Roberts-2013" TYPE="REFERENCE">Roberts 2013</LINK>).</P>
<P>There remains substantial practice variation amongst surgeons regarding the use of anticoagulation measures (<LINK REF="REF-Batra-2006" TYPE="REFERENCE">Batra 2006</LINK>). In daily clinical practice, there remains a huge variation in the way thromboprophylaxis is used. A recent survey among Dutch orthopedic and trauma surgeons showed that 60% to 80% always prescribed thromboprophylaxis in patients with lower-limb immobilization. Up to 8% of the participants never treated their patients with prophylaxis (<LINK REF="REF-van-Adrichem-2015" TYPE="REFERENCE">van Adrichem 2015</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-07-28 09:57:11 +0100" MODIFIED_BY="[Empty name]">
<P>Low molecular weight heparin is proven to be effective in the prevention of venous thromboembolism (<LINK REF="REF-Weitz-1997" TYPE="REFERENCE">Weitz 1997</LINK>). By treating patients with lower-limb immobilization with LMWH, we expect to see less venous thromboembolism compared to patients who do not receive any protection.</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-07-28 09:57:20 +0100" MODIFIED_BY="[Empty name]">
<P>This is the second update of the Cochrane review first published in 2008 (first update 2014). Since 2014, two additional studies on this subject have been published (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>). Therefore, in order to include the most recent information, we updated this review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-07-28 09:57:22 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of low molecular weight heparin for the prevention of venous thromboembolism in patients with lower-limb immobilization in an ambulant setting.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-07-28 09:58:44 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-07-28 09:57:39 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-07-28 09:57:26 +0100" MODIFIED_BY="[Empty name]">
<P>We considered all randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that describe thromboprophylaxis, by means of low molecular weight heparin (LMWH), in adults with lower-limb immobilization in an ambulatory setting. Treatment with LMWH could have started during hospital admission.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-07-28 09:57:33 +0100" MODIFIED_BY="[Empty name]">
<P>Adults treated with a device for lower-limb immobilization, such as a leg cast or brace, in an ambulatory setting. Weight bearing and duration of leg cast use were not considered criteria for inclusion or exclusion.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-07-28 09:57:34 +0100" MODIFIED_BY="[Empty name]">
<P>Studies comparing LMWH with no prophylaxis or placebo. Studies including oral anticoagulants, UFH, or aspirin were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-07-28 09:57:39 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-07-28 09:57:37 +0100" MODIFIED_BY="[Empty name]">
<P>Morbidity</P>
<UL>
<LI>DVT - confirmed by venography or ultrasonography</LI>
<LI>PE - confirmed by a ventilation-perfusion scan, a CT scan, or angiography</LI>
<LI>Symptomatic VTE - symptomatic DVT, PE, or combination</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-07-28 09:57:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mortality - PE-related</LI>
<LI>Mortality - other causes</LI>
<LI>Adverse outcomes of treatment: bleeding, heparin induced thrombocytopenia (HIT), allergic reaction, others (definitions of adverse outcomes as reported by study authors).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-07-28 09:57:48 +0100" MODIFIED_BY="[Empty name]">
<P> </P>
<ELECTRONIC_SEARCHES MODIFIED="2017-07-28 09:57:48 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, the Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials.</P>
<UL>
<LI>The Cochrane Vascular Specialised Register (19 April 2017).</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 3) via the Cochrane Register of Studies Online (searched 19 April 2017).</LI>
</UL>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used for CENTRAL.</P>
<P>The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE Ovid, Embase Ovid, CINAHL, and AMED, as well as through handsearching relevant journals. The full list of the databases, journals, and conference proceedings searched, as well as the search strategies used, are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Vascular module in the <A HREF="http://www.cochranelibrary.com">Cochrane Library</A>.</P>
<P>In addition, the CIS searched the following trials registers for details of ongoing and unpublished studies (19 April 2017). See <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1706201421203095205485308444738&amp;format=REVMAN#APP-02">Appendix 2</A>
</P>
<UL>
<LI>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch</A>).</LI>
<LI>ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">clinicaltrials.gov</A>)</LI>
<LI>International Standard Randomised Controlled Trial Number (ISRCTN) registry (<A HREF="http://www.isrctn.com/">www.isrctn.com</A>).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-11-21 12:02:41 +0000" MODIFIED_BY="Cathryn  A Broderick">
<P>The review authors searched the reference lists of relevant studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-07-28 09:58:44 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2017-07-28 09:57:49 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (KL and MH) independently assessed all studies identified by the literature searches, according to the inclusion criteria. Disagreements were resolved by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-07-28 09:57:50 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (MH and AZ) independently extracted data to ensure objectivity and validity of findings. A third review author (HJ) cross checked the information, and disagreements were resolved by discussion. The review authors contacted trial authors for additional information if required.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-07-28 09:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (KL and AZ) independently assessed the risk of bias of the included studies by using Cochrane's 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Random sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessors, incomplete outcome data, selective outcome reporting, and any other relevant biases were classified as 'low risk', 'high risk' or 'unclear risk'. They resolved any disagreement through discussion with review authors HJ and LJ.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-05-22 20:36:30 +0100" MODIFIED_BY="[Empty name]">
<P>We measured treatment effect by calculating odds ratios (OR) with 95% confidence interval (CI) for dichotomous data.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-07-28 09:58:07 +0100" MODIFIED_BY="[Empty name]">
<P>The individual participant was considered the unit of analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-07-28 09:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>Where appropriate, we used all randomized participants for the analysis. However, many of the included studies had participants excluded after randomization, creating a disparity between the number of participants randomized and the number available for assessment of VTE outcomes. Therefore, we used the data from the populations as reported by the studies. These generally consisted of all participants who received treatment and had evaluable testing of VTE at the end of the study. If these values were not available, we used the reported per-protocol data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-07-28 09:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>Statistical analysis was carried out using Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). Review author LJ coordinated the statistical analysis. We searched for clinical and statistical heterogeneity by visually inspecting the forest plots. We quantified statistical heterogeneity by means of an I² test (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We interpreted an I² value higher than 50% as an indicator for substantial heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-07-28 09:58:17 +0100" MODIFIED_BY="[Empty name]">
<P>We had planned to perform funnel plot analyses to assess reporting bias, when ten or more studies were included.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-07-28 09:58:19 +0100" MODIFIED_BY="[Empty name]">
<P>We synthesized available data using Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We investigated pooled estimates of the effects of treatment using a fixed-effect model to calculate ORs with 95% CIs for dichotomous outcomes. When substantial heterogeneity was detected, we performed a random-effects model analysis instead. If it was not possible to pool data, we planned to describe the results reported by the studies in the text.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-07-28 09:58:31 +0100" MODIFIED_BY="[Empty name]">
<P>We presented data by different groups of participants. These groups were selected, as these particular patient categories may influence the outcome.</P>
<UL>
<LI>DVT: regardless of type of plaster, whether operated or not</LI>
<LI>DVT: in below-knee cast, whether operated or not</LI>
<LI>DVT: only non-operated patients</LI>
<LI>DVT: only operated patients</LI>
<LI>DVT: fractures</LI>
<LI>DVT: soft-tissue injuries</LI>
<LI>DVT: distal segment</LI>
<LI>DVT: proximal segment</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-07-28 09:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>If any trials were judged to be of high risk of bias, we planned to perform a sensitivity analysis to assess outcomes with and without trials with high risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>We constructed a 'Summary of findings' table for the comparison LMWH compared to no prophylaxis or placebo in prevention of venous thromboembolism with lower-limb immobilization' using the GRADEpro GDT software to present the main findings of the review (<LINK REF="REF-GRADEpro-GDT-2015" TYPE="REFERENCE">GRADEpro GDT 2015</LINK>). We judged the outcomes deep venous thrombosis, pulmonary embolism, symptomatic venous thromboembolism, mortality due to pulmonary embolism, mortality due to other causes, and adverse outcomes, to be the most clinically relevant to healthcare professionals and patients. We calculated assumed control intervention risks from the mean number of events in the control groups of the selected studies for each outcome. We used the system developed by the GRADE Working Group to grade the quality of the evidence as high, moderate, low, or very low, based on within-study risk of bias, directness of evidence, heterogeneity, precision of effects estimates, and risk of publication bias (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-07-28 10:13:41 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-07-28 09:59:56 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-06-23 11:27:18 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-07-28 09:59:44 +0100" MODIFIED_BY="[Empty name]">
<P>We included eight RCTs (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>). The characteristics of these eight studies are summarized in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. All eight studies were reported as full papers and included a total of 3680 participants (range 105 to 1519). The participants included in the trials required lower-limb immobilization for the treatment of leg injuries such as foot and ankle fractures and achilles ruptures. All studies included participants prospectively, with quite similar exclusion criteria. The most common exclusion criteria were: pregnancy, allergy to heparin or contrast media, uncontrolled hypertension, pre-existing bleeding disorders, presence of malignancies, recent brain or gastrointestinal bleeding, previous DVT, and chronic venous insufficiency. Different LMWHs were used; they were administered once daily until removal of the plaster cast: nadroparin (2850 anti-XA IU) (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>), nadroparin (36 mg) (<LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>), certoparin (Mono-Embolex NM; 32 mg) (<LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>), tinzaparin (3500 anti-Xa IU) (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>), dalteparin (5000 IU) (<LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>), dalteparin (2500 IU or 5000 IU depending on body weight) <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>), and reviparin (1750 anti-XA IU) (<LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). There were no relevant differences between treatment and control groups regarding demographics or risk factors.</P>
<P>In two studies, plaster cast fitted following surgery was used as an exclusion criterion (<LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>). In one study, patients who underwent surgery before randomization might have had heparin treatment for up to four days before randomization (<LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). Another study treated all patients for one week with LMWH before randomization (<LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>). The included studies differed in the types of plaster cast (upper-leg, lower-leg, cylinder, or brace). There was also a variation in the duration of immobilization, ranging from 15 days (<LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>), to 43 days (<LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>).</P>
<P>In the included studies, the primary outcome parameter was DVT. Deep venous thrombosis, both symptomatic and asymptomatic, was diagnosed by means of ascending venography (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>), or ultrasound (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>). In these seven studies, every participant underwent a diagnostic exam. One study only performed ultrasound in participants who reported symptoms (<LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>).</P>
<P>Clinically-suspected PE had to be confirmed by ventilation-perfusion scintigraphy, angiography, or spiral CT-scanning. Information concerning the number of patients with symptomatic and asymptomatic DVT and the extent of the DVT was collected. Secondary outcome parameters were mortality and side effects in both treatment and control groups.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-07-28 09:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we excluded an additional nine studies, leading to a combined total of 47 excluded articles (<LINK REF="STD-Ayhan-2013" TYPE="STUDY">Ayhan 2013</LINK>; <LINK REF="STD-Cook-2011" TYPE="STUDY">Cook 2011</LINK>; <LINK REF="STD-Cvirn-2015" TYPE="STUDY">Cvirn 2015</LINK>; <LINK REF="STD-Garcia-2011" TYPE="STUDY">Garcia 2011</LINK>; <LINK REF="STD-Horner-2014" TYPE="STUDY">Horner 2014</LINK>; <LINK REF="STD-Lim-2015" TYPE="STUDY">Lim 2015</LINK>; <LINK REF="STD-Samama-2013" TYPE="STUDY">Samama 2013</LINK>; <LINK REF="STD-Saragas-2014" TYPE="STUDY">Saragas 2014</LINK>; <LINK REF="STD-Warot-2014" TYPE="STUDY">Warot 2014</LINK>). We stated the reasons for exclusion in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-07-28 10:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>
</P>
<ALLOCATION MODIFIED="2017-07-28 10:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>We judged five studies at low risk of random sequence generation (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>), and three trials to be of unclear risk of bias, because insufficient information was provided (<LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>). In two studies, participants were not recruited when study personnel were off duty (<LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>).</P>
<P>We judged three studies at low risk of random sequence generation (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>), and five trials to be of unclear risk of bias, because information on allocation concealment was not reported (<LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-07-28 10:00:23 +0100" MODIFIED_BY="[Empty name]">
<P>We judged four studies at high risk of performance bias, as they were open-label studies, with the control group receiving no prophylaxis (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>). We judged one study at low risk of performance bias, as participants and personnel were blinded to treatment assignment (<LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). We judged three studies to be of unclear risk of bias, as the blinding of study personnel was not explicitly reported (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>).</P>
<P>We judged two studies to be of unclear risk of detection bias, because no information on blinding of outcome assessors was provided (<LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). We judged the remainder of the included studies to be at low risk of detection bias (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-07-28 10:00:38 +0100" MODIFIED_BY="[Empty name]">
<P>We judged three studies at high risk of attrition bias, because the number of participants excluded from analysis was either high (higher than 30%) or reasons were not clearly described per treatment assignment (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>). We judged the remainder of the included studies to be at low risk of attrition bias, as the number of participants excluded from analyses was either low or clearly described (<LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-07-28 10:00:41 +0100" MODIFIED_BY="[Empty name]">
<P>We judged five studies to be at low risk of reporting bias, as all planned outcome measures, including adverse events, were reported (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>). We judged three studies to be of unclear risk of bias, since the methods sections of the study reports did not describe planned primary and secondary outcomes, therefore, we were unable to judge if all outcomes were reported (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>). <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK> reported on primary outcomes, but not on possible adverse events, therefore, we also judged it to be of unclear risk of reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-07-28 10:00:47 +0100" MODIFIED_BY="[Empty name]">
<P>We identified no other bias in the included studies and therefore, judged all included studies at low risk of other bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-07-28 10:13:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK> used a different study protocol, in which only patients with symptoms were examined using ultrasound. This can lead to an underestimation of the number of DVTs. Furthermore, primary asymptomatic DVT can still lead to late post-thrombotic syndrome. Therefore, we considered asymptomatic DVT to be a relevant clinical outcome. However, due to the large number of included participants, we deemed this study valuable for this review. In order not to obscure the primary outcome, we only used the data from <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK> in the pulmonary embolism and symptomatic VTE analyses.</P>
<SUBSECTION>
<HEADING LEVEL="3">Morbidity</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Deep venous thrombosis (DVT)</HEADING>
<P>Kujath and colleagues assessed 253 participants in their study, 126 of whom received a subcutaneous injection of Fraxiparin daily; 127 participants received no prophylaxis. Incidences of DVT were 16.5% (n = 21) in the control group and 4.8% (n = 6) in the LMWH group (odds ratio (OR) 0.25, 95% confidence interval (CI) 0.10 to 0.65; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>). Kock and colleagues assessed 163 participants in the control group (no treatment), and 176 participants in the LMWH once daily group. The incidence of DVT in the prophylaxis group was 0% versus 4.3% (n = 7) in the control group (OR 0.06, 95% CI 0.00 to 1.04; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>). In 2002, Jorgensen and colleagues published the results of their venographic-controlled study, and diagnosed DVT in 10 out of 99 participants in the treatment group and in 18 out of 106 participants in the control group. This difference was not significant (OR 0.55, 95% CI 0.24 to 1.26; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>). In 2002, Lassen and colleagues found an incidence of 35 of 188 participants randomly assigned to receive placebo (18.6%) and in 17 of 183 participants (9%) in the LMWH group (OR 0.45, 95% CI 0.24 to 0.83; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). Lapidus and colleagues published two studies in 2007. The study on thromboprophylaxis after surgical treatment of Achilles tendon rupture revealed a high incidence of thromboembolic events: 37% (18/49) in the treatment group versus 40% (19/47) in the placebo group (OR 0.86, 95% CI 0.38 to 1.95; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>). The study on prolonged thromboprophylaxis during immobilization after ankle surgery also showed a high incidences without a significant difference between groups: 21% in the treatment group versus 31% in the placebo group (OR 0.57, 95% CI 0.31 to 1.04; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>). In the first study published following the most recent update of this review in 2014, 719 participants received either dalteparin or nadroparin, 716 participants did not receive prophylaxis (<LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>). Incidences of clinical relevant DVT were 1.0% (n = 7) in the treatment group and 1.3% (n = 9) in the control group (OR 0.77, 95% CI 0.29 to 2.09). The most recent study assessed 186 participants, 92 of whom received nadroparin, and 94 of whom received no prophylaxis. The treatment group showed a DVT incidence of 2.2% (n = 2), which was significantly lower than the DVT incidence of 11.7% (n = 11) in the control group (OR 0.17, 95% CI 0.04 to 0.78; <LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Meta-analysis</HEADING>
<P>We conducted a meta-analysis to establish whether there was evidence of a thromboprophylactic effect of LMWH, to estimate the size of this effect, and to investigate whether it was consistent across the included studies. We combined all participants, and subsequently assessed the effect for different groups of participants: surgically-treated patients, patients with conservative treatment, patients with below-knee casts, patients with cylinder or above-knee casts, patients with fractures, patients with soft-tissue injuries, PE, distal or proximal DVT, and finally, the number of patients with symptomatic VTE.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">All participants, regardless of type of plaster, whether operated or not</HEADING>
<P>Seven studies, with a total of 1676 participants, had injuries of the lower limb immobilized by a plaster cast or brace (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). The control group (N = 834) received no prophylaxis or placebo; the prophylaxis group received LMWH once daily (N = 842). The incidence of thromboembolic events ranged from 4.3% to 40% in the control group (145/834), and from 0% to 37% (77/842) in the prophylaxis group (OR 0.45, 95% CI 0.33 to 0.61, P &lt; 0.001; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Participants with below-knee casts, whether operated or not</HEADING>
<P>We were able to obtain data on specific analyses of DVT in below-knee casts or braces from six studies (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK> and <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK> did not study the relationship between the type of cast and occurrence of thrombosis as part of their study designs. However, we could still add data from the group of participants with ruptured Achilles tendons from <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>. The incidences of DVT ranged from 0% to 37% in the LMWH groups, and from 3.6% to 40% in the control groups (OR 0.49, 95% CI 0.34 to 0.72; P &lt; 0.001; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; N = 1080).</P>
<P>Only <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK> provided data on participants with cylinder or above-knee casts, with a DVT incidence of 0/24 (0%) in the LMWH group and 2/24 (8.3%) in the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Only participants with conservative treatment (i.e. non-operated participants)</HEADING>
<P>Five studies provided details of DVT in conservatively treated participants (i.e. non-operated participants; <LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). When analyzed without consideration of type of cast or brace, the incidence ranged from 0% to 11.8% in the LMWH groups and from 4.3% to 17.3% in controls (OR 0.31, 95% CI 0.18 to 0.53, P &lt; 0.001; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; N = 974).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Only surgically-treated participants</HEADING>
<P>We obtained information about surgically-treated participants from four studies (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). The incidence of DVT in surgically-treated participants ranged from 7.2% to 37% in the LMWH group, and from 18.0% to 40% in the control group (OR 0.54, 95% CI 0.37 to 0.80, P = 0.002; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; N = 699).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fractures or soft-tissue injuries</HEADING>
<P>Six studies provided information on participants with fractures (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). These groups contained both surgically and conservatively treated participants. We found results in favour of the LMWH groups (OR 0.48, 95% CI 0.33 to 0.70, P &lt; 0.001; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; N = 1003). In participants with soft-tissue injury, we again found results in favour of the LMWH groups (OR 0.39, 95% CI 0.22 to 0.68, P &lt; 0.001; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; N = 658; <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Distal or proximal deep vein thrombosis</HEADING>
<P>Five studies provided information on the segment in which the thrombus was located (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>). The incidence of distal segment DVT, defined as below-knee DVT, ranged from 0% to 34.7% in participants who received LMWH, and from 2.5% to 34.0% in the control groups (OR 0.61, 95% CI 0.42 to 0.89, P = 0.009; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; N = 1208). Proximal DVT (above knee) was rare; there were eight events in a total of 614 participants who received LMWH (incidence ranged from 0% to 4.0%) versus 20/603 events in the controls (incidence ranged from 0.9% to 6.4%, OR 0.41, 95% CI 0.19 to 0.91, P = 0.03; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; N = 1217).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pulmonary embolism (PE)</HEADING>
<P>In the studies under review, PE was a rare complication in immobilization of the lower extremity. <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK> reported that one participant in the treatment group and four participants in the control group showed clinical signs of PE; in two of them, both in the control group, PE was confirmed by a ventilation-perfusion scan. <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK> reported that one participant in the group without prophylaxis showed clinical signs of a PE, but this diagnosis could not be proven by scintigraphic imaging. <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK> reported that four participants in the treatment group and five in the control group developed a PE, diagnosed with a spiral CT scan. In the PROTECT study, two participants in the control group developed a pulmonary embolism (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>). <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK> reported no cases of pulmonary embolism. Overall, no clear differences were found between the treatment and control groups (OR 0.50, 95% CI 0.17 to 1.47, P = 0.21; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; N = 2517).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic venous thromboembolism (VTE) - symptomatic deep venous thrombosis (DVT), pulmonary embolism (PE), or combination</HEADING>
<P>All studies but one reported on participants with symptomatic VTE. <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK> did not report on participants with a symptomatic DVT, because it was not clinically possible to differentiate symptoms of a possible DVT from those of normal postoperative findings. <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK> reported on two events in the LMWH group and six events in the placebo group. <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK> mentioned two participants with PE and four with symptomatic DVT, all of them in the placebo group. <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK> reported on nine symptomatic participants, however, it was not clear whether they were in the treatment group or not. For that reason, this study was not included in the pooled analysis. <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK> did not report on symptomatic participants in their Lancet publication, but additional information from participants with thrombosis was found in an earlier publication. Four participants in the control group showed symptoms of DVT. <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK> did not find any symptomatic VTEs. <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK> reported six participants with symptomatic DVT, three with PE and one with both DVT and PE in the LMWH group, and eight with DVT, four with PE, and one participant with both, in the control group. <LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK> reported two participants with a PE in the control group.</P>
<P>Symptomatic VTE was observed in 12 of 1469 (0.8%) participants receiving LMWH compared with 31 out of 1455 (2.1%) participants in the control group (OR 0.40, 95% CI 0.21 to 0.76; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; six RCTs; N = 2924).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Mortality (Pulmonary embolism- (PE)-related and other causes)</HEADING>
<P>
<LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK> reported one death in the no treatment group during their three-month follow-up after treatment; they reported that the death was assessed as possibly due to pulmonary embolism. However, a conclusive diagnosis could not be made because no autopsy was performed; the participant was over 90 years old and suffered from heart failure. The remaining seven studies reported no deaths due to PE (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>; N = 3111), or other causes (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>; N = 3111).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse outcomes of treatment</HEADING>
<P>Major side effects, such as hematoma, acute major bleeding, allergic reaction, and thrombocytopenia were rare.</P>
<P>
<LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK> reported 14 participants in the LMWH group and 12 in the placebo group had a bleeding event. <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK> also reported major bleeding occurred in two participants in the LMWH group (retroperitoneal bleeding in one and permanent discontinuation of LMWH due to minor bleeding in another) and one in the placebo group (permanent discontinuation of study medication due to minor bleeding). <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK> reported no cases of heparin induced thrombocytopenia (HIT). <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK> reported on five participants with minor complications (four small local hematomas, one facial eczema). <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK> reported no cases of HIT, hematomas, or severe bleeding. <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK> did not observe any side effects. Lapidus and colleagues did not report any cases of major bleeding (<LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>). <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK> reported one participant had a nosebleed after two days of dalteparin treatment. In <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>, two participants (one in each group) discontinued treatment due to minor bleeding. <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK> reported no major bleeds, one clinically relevant non-major bleed in the LMWH group, 55 minor bleeds in the treatment group, and 49 minor bleeds in the control group. <LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK> reported no major complications. Twenty-two participants in the treatment group reported minor bleeding, hematuria, or dark stool (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>).</P>
<P>Combining all reported adverse events into a random-effects model meta-analysis showed an OR of 2.01, 95% CI 0.83 to 4.86, I² = 57%, 3178 participants; 8 studies; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>See also <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-07-28 10:13:52 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-07-28 10:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>We included eight studies in this updated review, with a total of 3680 participants. From these studies, we found that the incidence of deep venous thrombosis (DVT), diagnosed by compression ultrasound, venography, or both, in participants with a leg injury who were immobilized in a plaster cast or brace for at least one week and received no thromboprophylaxis (or placebo) was 4.3% to 40%. This was significantly higher than for participants who received daily subcutaneous injections of low molecular weight heparin (LMWH) during the entire period of immobilization (0% to 37%).</P>
<P>Comparable results were seen in the following groups of participants: patients with a below-knee cast, surgically treated patients, conservatively treated patients (not surgically treated), patients with fractures, patients with soft-tissue injuries, and patients with proximal or distal DVT. The odds ratios (OR) between the individual participant groups were similar, with an overlap of the confidence intervals (CI). Therefore, it was not possible to indicate a participant or patient group where prophylaxis was not indicated. No clear differences were found for PE between LMWH and the control groups. The studies found less symptomatic venous thromboembolism (VTE) in the LMWH groups compared with the control groups. One death (in the control group) was reported in the included studies. Major adverse events were rare; the main adverse events reported were cases of minor bleeding.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-07-28 10:06:58 +0100" MODIFIED_BY="[Empty name]">
<P>The studies included in this review all assessed participants with lower-limb immobilization. Some studies only included conservatively treated participants, whereas, others also included surgically treated participants. Studies included participants with both fractures and soft-tissue injuries. These differences in inclusion criteria may have led to a lower external validity.</P>
<P>In addition to using Cochrane's 'Risk of bias' tool to assess methodological quality, we also assessed the validity and quality of the included randomized controlled trials using the scoring scheme provided on the website of Cochrane Netherlands (<A HREF="http://www.cochrane.nl">www.cochrane.nl</A>). The overall quality of the eight included studies according to this scoring system, was rated 'good', although some remarks should be added.</P>
<P>The true thromboembolic rate in unprotected patients remains unknown, as high-risk patients were excluded from participation in all eight studies, underestimating the incidence of thromboembolism in unprotected patients and the potentially beneficial effect of LMWHs. Although there is consensus among surgeons that thromboprophylaxis should be initiated in patients with a moderate to high risk for thromboembolism, there is no uniform definition of this patient group, leading to practice variation. Several attempts have been made to stratify the risk for VTE of immobilized patients (<LINK REF="REF-Gearhart-2000" TYPE="REFERENCE">Gearhart 2000</LINK>; <LINK REF="STD-Zagrodnick-1990" TYPE="STUDY">Zagrodnick 1990</LINK>). <LINK REF="STD-Knudson-2004" TYPE="STUDY">Knudson 2004</LINK> developed a scheme, based on analysis of 1602 episodes of VTE using the National Trauma Data Bank, to identify trauma patients with a high risk of thrombosis. Lower-limb fracture and age over 40 years were among the factors used for selection. However, this study also stated that with this scheme, 90% of patients with VTE would be identified, and 10% would be missed. By contrast, in another study, patients under 40 years of age, with soft-tissue injuries also developed DVT (<LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>). Up to now, no stratification method has proven its superiority or has gained general acceptance. In most studies in this review, investigators did not include patients with a high risk of DVT. So even in patients with a low to average risk of DVT, LMWH still provided significant protection.</P>
<P>In five studies, the included participants had a wide variety of trauma, ranging from fractures to soft-tissue injuries, and tendon ruptures (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>). Since the risk of DVT is found to be related to the presence and type of fracture, the extent of soft-tissue injury, and type and duration of surgery, heterogeneity might have been introduced. However, randomization should have minimized this effect. Three studies focused on participants with a specific trauma (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>). We also observed a high drop-out rate.</P>
<P>Five studies used ultrasound (<LINK REF="STD-Bruntink-2017" TYPE="STUDY">Bruntink 2017</LINK>; <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>; <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK>, <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>; <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>), and three used venography (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>), to diagnose DVT. The latter is considered the 'gold standard', but is rarely used in routine practice as the first line of investigation for DVT. Duplex ultrasonography and compression ultrasonography have a lower sensitivity and specificity compared to venography, especially for diagnosing calf vein thrombosis (<LINK REF="REF-CBO-2008" TYPE="REFERENCE">CBO 2008</LINK>; <LINK REF="REF-Lensing-1989" TYPE="REFERENCE">Lensing 1989</LINK>). This might be the reason for the differences in the results between <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK> and the studies that used venography (<LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK>; <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>; <LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK>), since there were no other major differences reported in participant characteristics or intervention. However, it does not explain the differences between the results of <LINK REF="STD-Kock-1995" TYPE="STUDY">Kock 1995</LINK>, <LINK REF="STD-Kujath-1993" TYPE="STUDY">Kujath 1993</LINK> and <LINK REF="STD-Lapidus-2007a" TYPE="STUDY">Lapidus 2007a</LINK>. By only examining participants reporting symptoms, <LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK> only reported clinically-relevant DVTs, therefore underestimating the number of DVTs in the study population. Due to this difference in study protocol, we only used the results of this study in the analyses for pulmonary embolism (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) and symptomatic VTE (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).<BR/>
</P>
<P>
<LINK REF="STD-Lassen-2002" TYPE="STUDY">Lassen 2002</LINK> included participants who received up to four days of LMWH (32% of participants). Another study treated all participants with LMWH for one week prior to randomization (<LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK>). This might equalize the effects in the two groups and lead to an underestimation of the treatment effect. Therefore, <LINK REF="STD-Lapidus-2007b" TYPE="STUDY">Lapidus 2007b</LINK> only focused on the duration of treatment, and not on the indication of treatment itself.</P>
<P>The dose of 3500 anti-Xa IU of tinzaparin that <LINK REF="STD-Jorgensen-2002" TYPE="STUDY">Jorgensen 2002</LINK> used might have been too low, since another study showed equal antithrombotic effect using 4500 anti-Xa IU of tinzaparin compared with 40 mg of enoxaparin, which is the standard dose in orthopedic surgery (<LINK REF="STD-Eriksson-2001" TYPE="STUDY">Eriksson 2001</LINK>). This possibly creates an underestimation of the effect of prophylaxis.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-07-28 10:07:11 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of evidence according GRADE varied by outcome and ranged from low to moderate with reasons for downgrading being risk of bias due to attrition and performance bias (DVT), imprecision and risk of bias due to attrition and performance bias (PE, symptomatic VTE and adverse outcomes) and low number of events and imprecision (mortality due to other causes).</P>
<P>See also <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>
</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-07-28 10:07:25 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently carried out study selection, data extraction, and study quality assessment in order to reduce bias and subjectivity. We are confident that all potential studies are included in this review. However, the possibility remains that relevant data exist which have not been published or were not found in the search.</P>
<P>The total number of included studies in this review was eight. Since ten studies are required to perform a funnel plot analysis, reliable funnel plot analysis could not be performed.</P>
<P>By only examining patient reporting symptoms Van Adrichem 2016 only reported clinical relevant DVTs, therefore underestimating the number of DVTs in the study population. Due to this difference in study protocol the results of this study were only used in the analyses for 'pulmonary embolism' (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) and 'symptomatic VTE' (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-07-28 10:13:52 +0100" MODIFIED_BY="[Empty name]">
<P>As early as 1944, the first study on deep venous thrombosis (DVT) following leg injuries was published, reporting incidence rates of 7% to 18% (<LINK REF="STD-Bauer-1944" TYPE="STUDY">Bauer 1944</LINK>). Nonfatal and fatal pulmonary embolism (PE) complicate DVT of the lower extremities. Fatal PE used to be a common cause of death in hospitals, because of the often clinically occult nature of DVT.</P>
<P>The discussion on the use of LMWH in immobilization of the lower limb focuses on the following issues: the reduction of symptomatic VTE, the reduction of asymptomatic DVT, the relevance of asymptomatic DVT, and the incidence of complications. With meta-analyses, we were able to show that the use of LMWH in immobilization of the lower limb following leg injury results in a reduction of symptomatic VTE and of (asymptomatic) DVT.</P>
<P>Over 80% of DVTs diagnosed were located distally. Calf vein thrombosis propagates and becomes proximal in between 0% and 25% of patients, accounting for a mean of 10%. Up to 10% of proximal DVTs embolize massively, and are potentially fatal (<LINK REF="REF-Anonymous-1986" TYPE="REFERENCE">Anonymous 1986</LINK>; <LINK REF="REF-Schellong-2007" TYPE="REFERENCE">Schellong 2007</LINK>). Opinions differ about the risk of post-thrombotic syndrome (PTS) after distal DVT. It is stated that the risk is considerably lower than in proximal DVT. Results are inconsistent for the relationship between the location of the initial thrombus and the subsequent development of PTS. Some prospective studies reported rates of PTS after distal DVT that were as high as 20% to 80% (<LINK REF="REF-McLafferty-1998" TYPE="REFERENCE">McLafferty 1998</LINK>; <LINK REF="REF-Schulman-1986" TYPE="REFERENCE">Schulman 1986</LINK>). Hence, distal DVT appears to be associated with a substantial risk of subsequent PTS. Further research is indicated to elicit the exact role of distal DVT in the development of PTS (<LINK REF="REF-Kahn-2006" TYPE="REFERENCE">Kahn 2006</LINK>).</P>
<P>The incidence of complications in the review seemed to be low compared with data in the literature. Major bleeding was reported in 0.27% (two out of 1469 participants) and minor bleeding in up to 7.8% of participants (<LINK REF="STD-Van-Adrichem-2017" TYPE="STUDY">Van Adrichem 2017</LINK>). In contrast, <LINK REF="STD-Reilmann-1993" TYPE="STUDY">Reilmann 1993</LINK> reported up to 14% of participants with hematomas due to injections. Another study even described it up to 28%, although some of the participants were not treated with LMWH, but with unfractionated heparin (<LINK REF="STD-Zagrodnick-1990" TYPE="STUDY">Zagrodnick 1990</LINK>). In our seven included studies, no cases of heparin-induced thrombocytopenia were described, which is in concordance with the observation that this condition is seldom seen in combination with LMWH (<LINK REF="REF-Bloemen-2012" TYPE="REFERENCE">Bloemen 2012</LINK>).</P>
<P>The eight studies used different types of LMWH. The total number of participants was insufficient to evaluate which type of LMWH to choose. Evidence published so far indicates that any differences between LMWH preparations, if they exist, must be extremely small (<LINK REF="REF-Geerts-2004" TYPE="REFERENCE">Geerts 2004</LINK>). It is unlikely that a properly sized and designed study comparing the various LMWHs will ever take place. Sample size calculations quickly reach over 10,000 if one considers appropriate definitions of 'non-inferiority' when comparing the various antithrombotic regimens (<LINK REF="REF-Vaitkus-2004" TYPE="REFERENCE">Vaitkus 2004</LINK>).</P>
<P>Venography is considered the most accurate method of diagnosing DVT but is now rarely used in clinical practice (<LINK REF="STD-Abelseth-1996" TYPE="STUDY">Abelseth 1996</LINK>; <LINK REF="REF-Bergqvist-2002" TYPE="REFERENCE">Bergqvist 2002</LINK>). It is an invasive procedure, and there is a reported incidence of serious adverse reactions to the contrast media in the range of 0.4% to 2% (<LINK REF="REF-Lensing-1990" TYPE="REFERENCE">Lensing 1990</LINK>). Duplex ultrasound is the most common non-invasive test used to diagnose venous thrombosis of the extremities. Compared with venography, ultrasound has been shown to be reliable in the diagnosis of proximal symptomatic DVT, with a sensitivity and specificity of over 90%. However, for distal thrombosis, a sensitivity of 73% can be reached when combining compression ultrasound with color-doppler ultrasound (<LINK REF="REF-CBO-2008" TYPE="REFERENCE">CBO 2008</LINK>). Considering the properties of the imaging methods used to diagnose PE, a recent systematic review showed a sensitivity of 86% for the ventilation-perfusion scintigraphy and a specificity of 46% compared with pulmonary angiography. For the CT scan, the percentages were 85% sensitivity and 94% specificity (<LINK REF="REF-Hayashino-2005" TYPE="REFERENCE">Hayashino 2005</LINK>). Consequently, the number of instances of missed DVT and PE seems to be acceptable when including studies with different diagnostic procedures, and should not influence our conclusions to a major extent. However, an underestimation of the incidence of VTE can occur when using ultrasound, CT-scan, or ventilation-perfusion scanning.</P>
<P>Increased incidence of DVT in an untreated population calls for measures, and thromboprophylaxis seems necessary if immobilization in a cast or brace is needed. Post-traumatic DVT can lead to PE or long-term damage in the form of PTS (<LINK REF="REF-Kakkar-1994" TYPE="REFERENCE">Kakkar 1994</LINK>). Low molecular weight heparin has been shown to be effective in reducing the incidence of VTE. The possible complications of major bleeding events (2/750 participants or 0.3%), and heparin-induced thrombopenia (none in this review) have been shown to be extremely rare, and do not outweigh the beneficial effect of the reduction of thromboses.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-07-28 10:08:34 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-07-28 10:08:15 +0100" MODIFIED_BY="[Empty name]">
<P>Moderate-quality evidence showed that the use of low molecular weight heparin (LMWH) in outpatients reduced the number of venous thromboembolic events when a plaster cast or brace was required, when compared with no prophylaxis or placebo.The quality of evidence was downgraded to 'moderate' due to risk of selection and attrition bias. Low-quality evidence showed no clear differences in PE between the LMWH and control groups, but less symptomatic VTE in the LMWH group. The quality of evidence was downgraded due to risk of bias and imprecision of results.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-07-28 10:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>Even with LMWH as a prophylactic measure, incidence rates of DVT, ranging from 0% to 10%, indicate a high absolute rate of morbidity in the population. In order to reduce the number of venous thromboembolic events, we encourage research to develop less immobilizing treatment options, and investigate further the use of other drugs such as the new oral anticoagulants (NOACs).</P>
<P>This review did not focus on the ongoing discussion of the clinical relevance of calf vein thrombosis. It simply confirmed its more frequent occurrence in immobilized patients. Future research might bring more clarity to the discussion on the significance of calf vein thrombosis.</P>
<P>Follow-up studies on long-term effects of DVT after immobilization, and the incidence of post-thrombotic syndrome in these patients, could yield valuable information on the clinical relevance of primary asymptomatic DVT.</P>
<P>Low molecular weight heparin treatment in all included studies was administered once daily until removal of the plaster cast. Nevertheless, the optimal period of treatment is unclear, and further research should be conducted to gain insight into this matter.</P>
<P>We did not focus on scoring systems and individual risk factors in this analysis. Future research might give more directives on specific advice for different patients or patient groups, based on patient and trauma characteristics.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-07-19 15:11:38 +0100" MODIFIED_BY="[Empty name]">
<P>The authors wish to acknowledge Dr M Testroote and Dr WAH Stigter for their contribution to previous versions of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-07-31 08:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>AZ: none known<BR/>KvL: none known<BR/>MvdH: none known<BR/>LJ: none known<BR/>HMJJ: none known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-07-28 10:08:36 +0100" MODIFIED_BY="[Empty name]">
<P>AZ analyzed data, writing<BR/>KvL assessed trial quality, extracted data.<BR/>MvdH assessed trial quality, extracted data.<BR/>LJ co-ordinated and advised on statistical methods, and redirected writing.<BR/>HMJJ cross-checked information, supervised and redirected writing<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-07-28 10:08:36 +0100" MODIFIED_BY="[Empty name]">
<P>'Risk of bias' and 'Summary of findings' tables added</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-08-07 15:45:34 +0100" MODIFIED_BY="Marlene Stewart">
<STUDIES MODIFIED="2017-07-27 17:32:51 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-07-27 17:32:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bruntink-2017" MODIFIED="2017-07-25 19:51:51 +0100" MODIFIED_BY="[Empty name]" NAME="Bruntink 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-07-25 19:47:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bruntink MM, Groutars YM, Schipper IB, Breederveld RS, Tuinebreijer WE, Derksen RJ; PROTECT Study Group</AU>
<TI>Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): a randomised controlled trial</TI>
<SO>Injury</SO>
<YR>2017</YR>
<VL>376</VL>
<PG>936-40</PG>
<IDENTIFIERS MODIFIED="2017-05-28 18:57:41 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418326"/><IDENTIFIER MODIFIED="2017-05-28 18:57:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="28279428"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-25 19:48:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derksen RJ, Groutars YME, Van de Brand JG</AU>
<TI>Trial setup and preliminary results of PROTECT: prophylaxis of thromboembolic complications trial</TI>
<SO>European Journal of Trauma and Emergency Surgery</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>Suppl 1</NO>
<PG>S141</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418327"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-25 19:51:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NTR1733</AU>
<TI>Prevention of thrombosis in patients who are treated with a plaster cast for a fracture of the ankle or foot</TI>
<SO>www.trialregister.nl/trialreg/admin/rctview.asp?TC=1733</SO>
<YR>(Date registered 23 March 2009)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418328"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-06-08 14:39:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418325"/><IDENTIFIER MODIFIED="2017-06-08 14:39:52 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorgensen-2002" MODIFIED="2017-07-27 13:39:56 +0100" MODIFIED_BY="[Empty name]" NAME="Jorgensen 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-07-27 13:39:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jorgensen PS, Warming , Hansen K, Paltred C, Berg H, Jensen R</AU>
<TI>Low molecular weight heparin (Innohep) thromboprophylaxis in outpatients with plaster casts. A phlebografic controlled study</TI>
<SO>Danish Orthopaedic Society Autumn Meeting</SO>
<YR>October 26-27 2000</YR>
<CY>Copenhagen, Denmark</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759821"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-25 19:52:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jorgensen PS, Warming T, Hansen K, Paltved C, Berg HV, Jensen R, et al</AU>
<TI>Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast; a venography controlled study</TI>
<SO>Thrombosis Research</SO>
<YR>2002</YR>
<VL>105</VL>
<NO>6</NO>
<PG>477-80</PG>
<IDENTIFIERS MODIFIED="2017-06-08 14:40:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-06-08 14:40:20 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759820"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759819"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kock-1995" MODIFIED="2017-07-25 20:00:55 +0100" MODIFIED_BY="[Empty name]" NAME="Kock 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kock HJ, Schmit-Neuerburg KP, Hanke J, Hakmann A, Althoff M, Rudofski G</AU>
<TI>Ambulatory prevention of thrombosis with low molecular weight heparin in plaster immobilization of the lower extremity</TI>
<SO>Vasa Supplementum</SO>
<YR>1992</YR>
<VL>35</VL>
<PG>105-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759823"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kock HJ, Schmit-Neuerburg KP, Hanke J, Hakmann A, Althoff M, Rudofsky G, et al</AU>
<TI>Ambulatory prevention of thrombosis with low molecular weight heparin in plaster immobilization of the lower extremity</TI>
<SO>Der Chirurg</SO>
<YR>1993</YR>
<VL>64</VL>
<NO>6</NO>
<PG>483-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759824"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-25 20:00:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kock HJ, Schmit-Neuerburg KP, Hanke J, Hakmann A, Althoff M, Rudofsky G</AU>
<TI>Ambulant thrombosis prophylaxis with low-molecular heparin in plaster immobilisation of the lower extremities</TI>
<SO>Hefte zur der Unfallchirurg</SO>
<YR>1993</YR>
<VL>232</VL>
<PG>245-6</PG>
<IDENTIFIERS MODIFIED="2017-07-25 20:00:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759825"/><IDENTIFIER MODIFIED="2017-07-25 20:00:52 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Article in German"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Karen Welch" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kock HJ, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H</AU>
<TI>Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg</TI>
<SO>Lancet</SO>
<YR>1995 Aug 19</YR>
<VL>346</VL>
<NO>8973</NO>
<PG>459-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759826"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kock HJ, Schmit-Neuerburg KP, Hanke J, Terwort A, Rudofsky G, Hirche H</AU>
<TI>Patient compliance during low molecular weight heparin thromboprophylaxis in outpatients with plaster cast immobilisation of the leg</TI>
<SO>Unfallchirurgie</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>6</NO>
<PG>319-28</PG>
<IDENTIFIERS MODIFIED="2013-12-11 13:21:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759827"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kock HJ, Schmitt-Neuerburg KP, Hanke J, Hakmann A, Althoff M, Rudofsky G</AU>
<TI>Prophylaxis of venous thromboembolism with low molecular weight heparin in surgical outpatients with immobilization of the lower limb by plaster cast</TI>
<SO>Haemostaseologie</SO>
<YR>1993</YR>
<VL>13 (suppl)</VL>
<PG>S36-S39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759828"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759822"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kujath-1993" MODIFIED="2017-07-25 20:03:48 +0100" MODIFIED_BY="[Empty name]" NAME="Kujath 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-07-25 20:02:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Habscheid W, Spannagel U, Kujath P, Schindler G</AU>
<TI>Prevention of thrombosis with low molecular weight heparin in ambulatory patients with injury of the lower extremity: an ultrasound study</TI>
<SO>Vasa Supplementum</SO>
<YR>1991</YR>
<VL>33</VL>
<PG>222-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759830"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kujath P, Eckmann C</AU>
<TI>Thromboembolism prophylaxis in ambulatory surgery</TI>
<SO>Aktuelle Chirurgie</SO>
<YR>1995</YR>
<VL>30</VL>
<NO>6</NO>
<PG>372-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759831"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kujath P, Spannagel U, Habscheid W, Schindler G, Weckbach A</AU>
<TI>Thrombosis prevention in outpatients with lower limb injuries</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1992</YR>
<VL>117</VL>
<NO>1</NO>
<PG>6-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759832"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-25 20:03:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kujath P, Spannagel U, Habscheid W</AU>
<TI>Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb</TI>
<SO>Haemostasis</SO>
<YR>1993</YR>
<VL>23</VL>
<NO>suppl 1</NO>
<PG>20-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759833"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759829"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapidus-2007a" MODIFIED="2017-07-25 20:04:22 +0100" MODIFIED_BY="[Empty name]" NAME="Lapidus 2007a" YEAR="2007">
<REFERENCE MODIFIED="2017-07-25 20:04:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapidus L, Rosfors S, Ponzer S, Levander C, Elvin A, Elvin G, et al</AU>
<TI>Prolonged thromboprophylaxis with dalteparin after surgical treatment of Achilles tendon rupture - a randomized, placebo-controlled study</TI>
<SO>Journal of Bone and Joint Surgery - British Volume</SO>
<YR>2009</YR>
<VL>91-B</VL>
<NO>Suppl 1</NO>
<PG>165</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759835"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-14 10:04:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lapidus LJ, Rosfors S, Ponzer S, Levander C, Elvin A, Laerfars G, et al</AU>
<TI>Prolonged thromboprophylaxis with Dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study</TI>
<SO>Journal of Orthopaedic Trauma</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>1</NO>
<PG>52-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759836"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759834"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapidus-2007b" MODIFIED="2014-04-14 10:04:11 +0100" MODIFIED_BY="[Empty name]" NAME="Lapidus 2007b" YEAR="2007">
<REFERENCE MODIFIED="2014-04-14 10:04:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapidus LJ, Ponzer S, Elvin A, Levander C, Laerfars G, Rosfors S, et al</AU>
<TI>Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized, placebo-controlled, double-blind study</TI>
<SO>Acta Orthopaedica</SO>
<YR>2007</YR>
<VL>78</VL>
<NO>4</NO>
<PG>528-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759838"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759837"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lassen-2002" MODIFIED="2017-07-27 17:32:42 +0100" MODIFIED_BY="[Empty name]" NAME="Lassen 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-07-27 17:32:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmad S, Bacher HP, Lassen MR, Hoppensteadt DA, Leitz H, Misselwitz F, et al</AU>
<TI>Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopaedic patients</TI>
<SO>Archives of Pathology and Laboratory Medicine</SO>
<YR>2003</YR>
<VL>127</VL>
<NO>5</NO>
<PG>584-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418329"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-11 13:24:20 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lassen MR, Borris LC, Nakov RL</AU>
<TI>Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>10</NO>
<PG>726-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759839"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Van-Adrichem-2017" MODIFIED="2017-07-27 13:40:44 +0100" MODIFIED_BY="[Empty name]" NAME="Van Adrichem 2017" YEAR="2016">
<REFERENCE MODIFIED="2017-07-25 20:05:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01542762</AU>
<TI>Pot-Cast: thrombosis prophylaxis during plaster cast lower leg immobilisation</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01542762?term=nct01542762&amp;rank=1</SO>
<YR>(Date first received 27 February 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418331"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-27 13:40:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB, et al</AU>
<TI>Thromboprophylaxis after knee arthroscopy and lower-leg casting</TI>
<SO>New England Journal of Medicine</SO>
<YR>2017</YR>
<VL>376</VL>
<NO>6</NO>
<PG>515-25</PG>
<IDENTIFIERS MODIFIED="2017-02-06 14:11:30 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418332"/><IDENTIFIER MODIFIED="2017-02-06 14:11:30 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="27959702"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-02-06 14:04:20 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418330"/><IDENTIFIER MODIFIED="2017-02-06 14:04:20 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1056/NEJMoa1613303"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-07-27 17:32:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abelseth-1996" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Abelseth 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abelseth G, Buckley RE, Pineo GE, Hull R, Rose MS</AU>
<TI>Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip</TI>
<SO>Journal of Orthopaedic Trauma</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>4</NO>
<PG>230-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759842"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759841"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ageno-2004" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Ageno 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ageno W, Dentali F, Imberti D</AU>
<TI>A survey of thrombosis prophylaxis use in patients with lower limb fractures</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>92</VL>
<NO>5</NO>
<PG>1166-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759844"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759843"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1991" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Anonymous 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Low molecular weight heparin in the prevention of thrombosis during plaster cast immobilization</TI>
<SO>Therapiewoche</SO>
<YR>1991</YR>
<VL>41</VL>
<NO>43</NO>
<PG>2774</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759848"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759847"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1995" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Anonymous 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Plaster cast immobilization and deep vein thrombosis</TI>
<TO>Immobilisation platree et thrombose veineuse profonde</TO>
<SO>Sang Thrombose Vaisseaux</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>9</NO>
<PG>641-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759850"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759849"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Armbrecht-1993" MODIFIED="2017-07-25 20:08:20 +0100" MODIFIED_BY="[Empty name]" NAME="Armbrecht 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-07-25 20:08:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armbrecht A, Zenker W, Egbers HJ, Havemann D</AU>
<TI>Plaster-free, early functional after-care of surgically managed Achilles tendon rupture</TI>
<SO>Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen</SO>
<YR>1993</YR>
<VL>64</VL>
<NO>11</NO>
<PG>926-30</PG>
<IDENTIFIERS MODIFIED="2017-07-25 20:08:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759852"/><IDENTIFIER MODIFIED="2017-07-25 20:08:18 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Article in German"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759851"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ayhan-2013" MODIFIED="2017-06-21 14:32:45 +0100" MODIFIED_BY="[Empty name]" NAME="Ayhan 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-06-21 14:32:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayhan H, Iyigun E, Ince S, Can MF, Hatipoglu S, Saglam M</AU>
<TI>Comparison of three different protocols in the prevention of postoperative deep vein thrombosis in patients at high-risk: randomized clinical study</TI>
<SO>European Surgical Research</SO>
<YR>2013</YR>
<VL>50</VL>
<PG>64-5</PG>
<IDENTIFIERS MODIFIED="2017-03-02 07:14:39 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418334"/><IDENTIFIER MODIFIED="2017-03-02 07:14:39 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23736377"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-03-02 07:04:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418333"/><IDENTIFIER MODIFIED="2017-03-02 07:04:17 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1159/000351978"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bauer-1944" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Bauer 1944" YEAR="1944">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauer G</AU>
<TI>Thrombosis following leg injuries</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1944</YR>
<VL>90</VL>
<PG>229-49</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759854"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759853"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breyer-1984" MODIFIED="2013-12-11 12:59:24 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Breyer 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-12-11 12:59:24 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breyer H, Koppenhagen K, Mabiki M, Rahmanzadeh R</AU>
<TI>The risk of thromboembolism due to plaster cast immobilisation and operation of the lower extremity</TI>
<TO>Thromboserisko durch Gipsimmobilisation und Operation an der unteren Extremitaet</TO>
<SO>Hefte zur Unfallheilkunde</SO>
<YR>1984</YR>
<VL>164</VL>
<PG>423-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759856"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759855"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bridges-2003" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Bridges 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bridges GG, Lee MD, Jenkins JK, Stephens MA, Croce MA, Fabian TC</AU>
<TI>Expedited discharge in trauma patients requiring anticoagulation for deep venous thrombosis prophylaxis: the LEAP Program</TI>
<SO>Journal of Trauma: Injury Infection and Critical Care</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>2</NO>
<PG>232-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759858"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759857"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cook-2011" MODIFIED="2017-06-20 14:42:18 +0100" MODIFIED_BY="[Empty name]" NAME="Cook 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-06-20 14:42:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cook D, Meade M, Guyatt G, Walter SD, Heels-Ansdell D, Geerts W, et al</AU>
<TI>PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan</TI>
<SO>Journal of Critical Care</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>2</NO>
<PG>223.e1-9</PG>
<IDENTIFIERS MODIFIED="2016-11-30 12:15:48 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418336"/><IDENTIFIER MODIFIED="2016-11-30 12:15:48 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21482348 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-11-30 12:12:40 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418335"/><IDENTIFIER MODIFIED="2016-11-30 12:12:40 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jcrc.2011.02.010"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cvirn-2015" MODIFIED="2017-06-21 14:24:05 +0100" MODIFIED_BY="[Empty name]" NAME="Cvirn 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-06-21 14:24:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cvirn G, Waha JE, Ledinski G, Schlagenhauf A, Leschnik B, Koestenberger M, et al</AU>
<TI>Bed rest does not induce hypercoagulability</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2015 Jan</YR>
<VL>45</VL>
<NO>1</NO>
<PG>63-9</PG>
<IDENTIFIERS MODIFIED="2016-10-02 14:47:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418338"/><IDENTIFIER MODIFIED="2016-10-02 14:47:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25413567 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-10-02 14:05:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418337"/><IDENTIFIER MODIFIED="2016-10-02 14:05:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/eci.12383"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eriksson-2001" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Eriksson 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson BI, Bauer KA, Lassen MR, Turpie AG</AU>
<TI>Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>18</NO>
<PG>1298-304</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759860"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759859"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeark-1967" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Freeark 1967" YEAR="1967">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeark RJ, Boswick J, Fardin R</AU>
<TI>Posttraumatic venous thrombosis</TI>
<SO>Archives of Surgery</SO>
<YR>1967</YR>
<VL>95</VL>
<NO>4</NO>
<PG>567-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759862"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759861"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Garcia-2011" MODIFIED="2017-06-21 14:23:22 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-06-21 14:23:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia DA</AU>
<TI>ACP Journal Club. Dalteparin did not differ from unfractionated heparin for reducing proximal DVT in critically ill patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>155</VL>
<NO>2</NO>
<PG>JC1-7</PG>
<IDENTIFIERS MODIFIED="2016-11-29 13:16:19 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418340"/><IDENTIFIER MODIFIED="2016-11-29 13:16:19 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21768573"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-11-29 13:06:35 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418339"/><IDENTIFIER MODIFIED="2016-11-29 13:06:35 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.7326/0003-4819-155-2-201107190-02007"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geerts-1994" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Geerts 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geerts WH, Code KI, Jay RM, Chen E, Szalai JP</AU>
<TI>A prospective study of venous thromboembolism after major trauma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>24</NO>
<PG>1601-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759864"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759863"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geerts-1996" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Geerts 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, et al</AU>
<TI>A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<NO>10</NO>
<PG>701-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759866"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759865"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gehling-1994" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Gehling 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gehling H, Leppek R, Kunneke M, Gotzen L, Giannadakis K, Henkel J</AU>
<TI>Is prevention of thromboembolism in ambulatory and conservative therapy of rupture of the fibular ligament of the upper ankle joint necessary?</TI>
<SO>Unfallchirurg</SO>
<YR>1994</YR>
<VL>97</VL>
<NO>7</NO>
<PG>362-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759868"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759867"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gehling-1998" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Gehling 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gehling H, Giannadakis K, Lefering R, Hessmann M, Achenbach S, Gotzen L</AU>
<TI>A comparison of acetylsalicylic acid with low-molecular-weight heparin for prophylaxis of deep-vein thrombosis in outpatients with injuries and immobilizing bandages of the lower limb</TI>
<SO>Unfallchirurg</SO>
<YR>1998</YR>
<VL>101</VL>
<NO>1</NO>
<PG>42-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759870"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759869"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannadakis-2000" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Giannadakis 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannadakis K, Gehling H, Sitter H, Achenbach S, Hahne H, Gotzen L</AU>
<TI>Is a general pharmacologic thromboembolism prophylaxis necessary in ambulatory treatment by plaster cast immobilization in lower limb injuries?</TI>
<SO>Unfallchirurg</SO>
<YR>2000</YR>
<VL>103</VL>
<NO>6</NO>
<PG>475-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759872"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759871"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goel-2009" MODIFIED="2017-07-25 20:11:00 +0100" MODIFIED_BY="[Empty name]" NAME="Goel 2009" YEAR="2009">
<REFERENCE MODIFIED="2017-07-25 20:11:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goel DP, Buckley R, de Vries G, Abelseth G, Ni A, Gray R</AU>
<TI>Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial</TI>
<SO>Journal of Bone and Joint Surgery - British Volume</SO>
<YR>2009</YR>
<VL>91-B</VL>
<PG>388-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759874"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759873"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenfield-1997" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Greenfield 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J</AU>
<TI>Posttrauma thromboembolism prophylaxis</TI>
<SO>Journal of Trauma: Injury Infection and Critical Care</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>1</NO>
<PG>100-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759876"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759875"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haas-1989" MODIFIED="2017-07-25 20:11:40 +0100" MODIFIED_BY="[Empty name]" NAME="Haas 1989" YEAR="1989">
<REFERENCE MODIFIED="2017-07-25 20:11:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haas S, Biegholdt M</AU>
<TI>Prevention of thromboembolism with low molecular weight heparin</TI>
<TO>Ambulante thromboembolieprophylaxe mit niedermolekularem heparin</TO>
<SO>Hamostaseologie</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>5</NO>
<PG>237-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759878"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759877"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harenberg-1998" MODIFIED="2017-07-25 20:12:00 +0100" MODIFIED_BY="[Empty name]" NAME="Harenberg 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-07-25 20:12:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harenberg J, Piazolo L, Misselwitz F</AU>
<TI>Prevention of thromboembolism with low-molecular-weight heparin in ambulatory surgery and unoperated surgical and orthopedic patients</TI>
<SO>Zentralblatt Chirurgie</SO>
<YR>1998</YR>
<VL>123</VL>
<NO>11</NO>
<PG>1284-7</PG>
<IDENTIFIERS MODIFIED="2017-07-25 20:11:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759880"/><IDENTIFIER MODIFIED="2017-07-25 20:11:57 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Article in German"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759879"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hjelmstedt-1968" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Hjelmstedt 1968" YEAR="1968">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hjelmstedt A, Bergvall U</AU>
<TI>Incidence of thrombosis in patients with tibial fractures</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1968</YR>
<VL>134</VL>
<NO>3</NO>
<PG>209-18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759882"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759881"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Horner-2014" MODIFIED="2017-07-25 20:12:21 +0100" MODIFIED_BY="[Empty name]" NAME="Horner 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-07-25 20:12:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horner D, Hogg K, Body R, Nash MJ, Baglin T, Mackway-Jones K</AU>
<TI>The anticoagulation of calf thrombosis (ACT) project: results from the randomized controlled external pilot trial</TI>
<SO>Chest</SO>
<YR>2014 Dec</YR>
<VL>146</VL>
<NO>6</NO>
<PG>1468-77</PG>
<IDENTIFIERS MODIFIED="2016-10-02 13:59:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418342"/><IDENTIFIER MODIFIED="2016-10-02 13:59:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25010443 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-10-02 13:51:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418341"/><IDENTIFIER MODIFIED="2016-10-02 13:51:08 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1378/chest.14-0235"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kannus-1991" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Kannus 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kannus P, Renström P</AU>
<TI>Treatment for acute tears of the lateral ligaments of the ankle</TI>
<SO>Journal of Bone and Joint Surgery - American Volume</SO>
<YR>1991</YR>
<VL>73-A</VL>
<NO>2</NO>
<PG>305-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759884"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759883"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knudson-1996" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Knudson 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knudson MM, Morabito D, Paiement GD, Shackleford S</AU>
<TI>Use of low molecular weight heparin in preventing thromboembolism in trauma patients</TI>
<SO>Journal of Trauma: Injury Infection and Critical Care</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>3</NO>
<PG>446-59</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759886"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759885"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knudson-2004" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Knudson 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen L</AU>
<TI>Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank</TI>
<SO>Annals of Surgery</SO>
<YR>2004</YR>
<VL>240</VL>
<NO>3</NO>
<PG>490&#8211;6, discussion 496-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759888"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759887"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kudsk-1989" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Kudsk 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kudsk KA, Fabian TC, Baum S, Gold RE, Mangiante E, Voeller G</AU>
<TI>Silent deep vein thrombosis in immobilized multiple trauma patients</TI>
<SO>American Journal of Surgery</SO>
<YR>1989</YR>
<VL>158</VL>
<NO>6</NO>
<PG>515-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759890"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759889"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lassen-2000" MODIFIED="2008-07-21 14:39:40 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Lassen 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-07-21 14:39:40 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lassen M, Boris L, Backer P, Nakov R, Fareed J</AU>
<TI>Efficacy and safety of low molecular weight heparin (Elivarine) in the prophylaxis of venous thromboembolism in patients with brace immobilization after injury of the lower extremity</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<PG>491A</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759892"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759891"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lim-2015" MODIFIED="2017-07-25 20:13:54 +0100" MODIFIED_BY="[Empty name]" NAME="Lim 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-07-25 20:13:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F, et al</AU>
<TI>Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients</TI>
<SO>Critical Care Medicine</SO>
<YR>2015</YR>
<VL>43</VL>
<NO>2</NO>
<PG>401-10</PG>
<IDENTIFIERS MODIFIED="2016-11-30 12:02:25 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418344"/><IDENTIFIER MODIFIED="2016-11-30 12:02:25 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25474533 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-11-30 11:58:05 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418343"/><IDENTIFIER MODIFIED="2016-11-30 11:58:05 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/CCM.0000000000000713"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lippert-1995" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Lippert 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lippert H</AU>
<TI>Prevention of venous thromboembolism beyond the period of hospitalisation and during out-of-hospital surgery</TI>
<SO>Hamostaseologie</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>3</NO>
<PG>167-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759894"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759893"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marlovits-2007" MODIFIED="2017-07-27 13:41:08 +0100" MODIFIED_BY="[Empty name]" NAME="Marlovits 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-06-21 14:19:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marlovits S, Striessnig G, Schuster R, Stocker R, Luxl M, Trattnig S, et al</AU>
<TI>A prospective, randomized, placebo-controlled study of extended-duration post-discharge thromboprophylaxis with enoxaparin following arthroscopic reconstruction of the anterior cruciate ligament</TI>
<SO>Blood</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>11</NO>
<PG>1764</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759896"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-27 13:41:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marlovits S, Striessnig G, Schuster R, Stocker R, Luxl M, Trattnig S, et al</AU>
<TI>Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study</TI>
<SO>Arthroscopy</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>7</NO>
<PG>696-702</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759897"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759895"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinole-2003" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Martinole 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinole A</AU>
<TI>Heparin prophylaxis for a leg cast?</TI>
<SO>Prescrire International</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>66</NO>
<PG>159</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759899"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759898"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Micheli-1975" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Micheli 1975" YEAR="1975">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Micheli LJ</AU>
<TI>Thromboembolic complications of cast immobilization for injuries of the lower extremities</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1975</YR>
<VL>108</VL>
<PG>191-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759901"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759900"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00843492" MODIFIED="2017-07-25 20:17:32 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00843492" YEAR="">
<REFERENCE MODIFIED="2017-07-25 20:17:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00843492</AU>
<TI>A study to evaluate the efficacy and safety of fondaparinux for the prevention of venous blood clots in patients with a plaster cast or other type of immobilization for a below-knee injury not needing surgery (FONDACAST)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00843492</SO>
<YR>(First received 11 December 2008)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759903"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759902"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nesheiwat-1996" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Nesheiwat 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nesheiwat F, Sergi AR</AU>
<TI>Deep venous thrombosis and pulmonary embolism following cast immobilization of the lower extremity</TI>
<SO>Journal of Foot and Ankle Surgery</SO>
<YR>1996</YR>
<VL>35</VL>
<NO>6</NO>
<PG>590-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759905"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759904"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reilmann-1988" MODIFIED="2017-06-21 14:17:44 +0100" MODIFIED_BY="[Empty name]" NAME="Reilmann 1988" YEAR="1988">
<REFERENCE MODIFIED="2017-06-21 14:17:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reilmann H, Bosch U, Barthels M</AU>
<TI>Prevention of thromboembolism in surgery</TI>
<SO>Orthopade</SO>
<YR>1988</YR>
<VL>17</VL>
<NO>1</NO>
<PG>110-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759907"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759906"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reilmann-1993" MODIFIED="2017-07-25 20:18:33 +0100" MODIFIED_BY="[Empty name]" NAME="Reilmann 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-07-25 20:18:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reilmann H, Weinberg AM, Forster EE, Happe B</AU>
<TI>Prevention of thrombosis in ambulatory patients</TI>
<SO>Orthopade</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>2</NO>
<PG>117-20</PG>
<IDENTIFIERS MODIFIED="2017-07-25 20:18:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759909"/><IDENTIFIER MODIFIED="2017-07-25 20:18:31 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Article in German"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759908"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Samama-2013" MODIFIED="2017-07-27 13:41:18 +0100" MODIFIED_BY="[Empty name]" NAME="Samama 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-07-27 13:41:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Samama CM, Lecoules N, Kierzek G, Claessens YE, Riou B, Rosencher N, et al</AU>
<TI>Comparison of fondaparinux with low molecular weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2013</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1833-43</PG>
<IDENTIFIERS MODIFIED="2017-03-02 07:35:51 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418346"/><IDENTIFIER MODIFIED="2017-03-02 07:35:51 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23965181"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-20 14:51:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samama CM, Lecoules N, Kierzek G, Claessens YE, Riou B, Rosencher N, et al</AU>
<TI>Comparison of fondaparinux with low-molecular-weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid Immobilization for isolated non-surgical below-knee injury</TI>
<TO>Étude comparant le fondaparinux à une héparine de bas poidsmoléculaire dans la prévention de la maladie thromboembolique veineuseen cas d&#8217;immobilisation rigide ou semi-rigide après traumatisme isolénon chirurgical du membre inférieur au-dessous du genou</TO>
<SO>Annales Francaises de Medecine d'Urgence</SO>
<YR>2014</YR>
<VL>4</VL>
<NO>3</NO>
<PG>153-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418347"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-03-02 07:33:32 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418345"/><IDENTIFIER MODIFIED="2017-03-02 07:33:32 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/jth.12395"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Saragas-2014" MODIFIED="2017-07-25 20:19:42 +0100" MODIFIED_BY="[Empty name]" NAME="Saragas 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-07-25 20:19:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saragas NP, Ferrao PN, Saragas E, Jacobson BF</AU>
<TI>The impact of risk assessment on the implementation of venous thromboembolism prophylaxis in foot and ankle surgery</TI>
<SO>Foot and Ankle Surgery</SO>
<YR>2014 Jun</YR>
<VL>20</VL>
<NO>2</NO>
<PG>85-9</PG>
<IDENTIFIERS MODIFIED="2016-11-30 12:07:56 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418349"/><IDENTIFIER MODIFIED="2016-11-30 12:07:56 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24796824 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-11-30 12:05:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418348"/><IDENTIFIER MODIFIED="2016-11-30 12:05:29 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.fas.2013.11.002"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schultz-2004" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Schultz 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schultz DJ, Brasel KJ, Washington L, Goodman LR, Quickel RR, Lipchik RJ, et al</AU>
<TI>Incidence of asymptomatic pulmonary embolus in moderately to severely injured trauma patients</TI>
<SO>Journal of Trauma: Injury Infection and Critical Care</SO>
<YR>2004</YR>
<VL>56</VL>
<NO>4</NO>
<PG>727-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759911"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759910"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selby-2010" MODIFIED="2017-07-27 13:41:25 +0100" MODIFIED_BY="[Empty name]" NAME="Selby 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-06-20 14:45:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selby R, Geerts WH, Kreder HJ, Crowther MA, Kaus L, Sealey F</AU>
<TI>A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures</TI>
<SO>Journal of Orthopaedic Trauma</SO>
<YR>2015</YR>
<VL>29</VL>
<NO>5</NO>
<PG>224-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418350"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-27 13:41:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Selby R, Geerts WH, Kreder HJ, Crowther MA, Kaus L, Sealey F</AU>
<TI>Clinically important venous thromboembolism (CIVTE) following isolated leg fractures distal to the knee: epidemiology &amp; prevention: the D-KAF (dalteparin in knee-to-ankle fracture) trial</TI>
<SO>Journal of Bone and Joint Surgery - British Volume</SO>
<YR>2010</YR>
<VL>92-B</VL>
<NO>Suppl 1</NO>
<PG>7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759913"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759912"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spieler-1972" MODIFIED="2017-07-25 20:20:43 +0100" MODIFIED_BY="[Empty name]" NAME="Spieler 1972" YEAR="1972">
<REFERENCE MODIFIED="2017-07-25 20:20:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spieler U, Preter B, Brunner U</AU>
<TI>Traumatic thromboses of the deep venous system in recent tibial fractures</TI>
<TO>Traumatische thrombosen im tiefen venensystem bei frischen unterschenkelfrakturen</TO>
<SO>Schweizerische Medizinische Wochenschrift</SO>
<YR>1972</YR>
<VL>102</VL>
<NO>43</NO>
<PG>1535-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759915"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759914"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Warot-2014" MODIFIED="2017-06-21 14:17:08 +0100" MODIFIED_BY="[Empty name]" NAME="Warot 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-21 14:17:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warot M, Synowiec T, Wencel-Warot A, Daroszewski P, Bojar I, Micker M, et al</AU>
<TI>Can deep vein thrombosis be predicted after varicose vein operation in women in rural areas?</TI>
<SO>Annals of Agricultural and Environmental Medicine</SO>
<YR>2014</YR>
<VL>21</VL>
<NO>3</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2016-10-02 14:52:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6418352"/><IDENTIFIER MODIFIED="2016-10-02 14:52:35 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 25292137 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-10-02 14:50:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6418351"/><IDENTIFIER MODIFIED="2016-10-02 14:50:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.5604/12321966.1120610"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-1992" MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" NAME="Wolf 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-12-19 10:15:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf N, Meiser H, Berg U, Goedicke M, Simonis G</AU>
<TI>Ambulatory prevention of thrombosis in a traumatologic patient sample</TI>
<SO>Vasa Supplementum</SO>
<YR>1992</YR>
<VL>35</VL>
<PG>109</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759917"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759916"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zagrodnick-1990" MODIFIED="2017-07-25 20:21:22 +0100" MODIFIED_BY="[Empty name]" NAME="Zagrodnick 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-07-25 20:21:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zagrodnick J, Kaufner HK</AU>
<TI>Ambulatory thromboembolism prevention in traumatology using self-injection of heparin</TI>
<SO>Unfallchirurg</SO>
<YR>1990</YR>
<VL>93</VL>
<NO>7</NO>
<PG>331-3</PG>
<IDENTIFIERS MODIFIED="2017-07-25 20:21:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2759919"/><IDENTIFIER MODIFIED="2017-07-25 20:21:18 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Article in German"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2759918"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-06-08 14:36:51 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2017-06-08 14:37:03 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-07-28 10:20:06 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-07-28 10:20:06 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Anderson-2003" MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Anderson FA, Spencer F A</AU>
<TI>Risk factors for venous thromboembolism</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<NO>23 suppl 1</NO>
<PG>I-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-1986" MODIFIED="2013-12-11 14:20:27 +0000" MODIFIED_BY="[Empty name]" NAME="Anonymous 1986" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Consensus conference: prevention of venous thrombosis and pulmonary embolism</TI>
<SO>JAMA</SO>
<YR>1986</YR>
<VL>256</VL>
<NO>6</NO>
<PG>744-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atkins-2004" MODIFIED="2017-07-27 16:14:49 +0100" MODIFIED_BY="[Empty name]" NAME="Atkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Batra-2006" MODIFIED="2013-10-17 10:29:15 +0100" MODIFIED_BY="[Empty name]" NAME="Batra 2006" TYPE="JOURNAL_ARTICLE">
<AU>Batra S, Kurup H, Gul A, Andrew JG</AU>
<TI>Thromboprophylaxis following cast immobilisation for lower limb injuries-survey of current practice in United Kingdom</TI>
<SO>Injury</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>9</NO>
<PG>813&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergqvist-2002" MODIFIED="2013-12-11 14:40:39 +0000" MODIFIED_BY="[Empty name]" NAME="Bergqvist 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Lowe G</AU>
<TI>Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<NO>19</NO>
<PG>2173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bloemen-2012" MODIFIED="2017-06-20 14:43:36 +0100" MODIFIED_BY="[Empty name]" NAME="Bloemen 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bloemen A, Testroote MJ, Janssen-Heijnen ML, Janzing HM</AU>
<TI>Incidence and diagnosis of heparin-induced thrombocytopenia (HIT) in patients with traumatic injuries treated with unfractioned or low-molecular-weight heparin: a literature review</TI>
<SO>Injury</SO>
<YR>2012</YR>
<VL>43</VL>
<PG>548-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CBO-2008" MODIFIED="2017-06-21 14:16:16 +0100" MODIFIED_BY="[Empty name]" NAME="CBO 2008" TYPE="OTHER">
<AU>CBO (Centraal Begeleidingsorgaan voor de intercollegiale toetsing)</AU>
<TI>Concept directive diagnostics, prevention and treatment of venous thromboembolism and secondary prevention of arterial thrombosis</TI>
<TO>Conceptrichtlijn diagnostiek, preventie en behandeling van veneuze tromboembolie en secundaire preventie arterie&#776;le trombose</TO>
<SO>Quality Institute for Health Care (Kwaliteitsinstituut voor de Gezondheidszorg), the Netherlands (http://www.cvgk.nl/legacy/bestanden/CBO-richtlijn-Stolling-2009.pdf)</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clagett-1995" MODIFIED="2013-10-17 10:29:15 +0100" MODIFIED_BY="[Empty name]" NAME="Clagett 1995" TYPE="JOURNAL_ARTICLE">
<AU>Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB</AU>
<TI>Prevention of venous thromboembolism</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>108</VL>
<NO>4 Suppl</NO>
<PG>312S&#8211;34S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2017-03-16 13:12:00 +0000" MODIFIED_BY="Cathryn  Broderick" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Della-Rocca-2013" MODIFIED="2017-06-21 14:11:37 +0100" MODIFIED_BY="[Empty name]" NAME="Della Rocca 2013" TYPE="JOURNAL_ARTICLE">
<AU>Della Rocca G, Danelli G, Randelli F, Romanini E, Biggi F, Laurora NR, et al</AU>
<TI>II Italian intersociety consensus statement on antithrombotic prophylaxis in orthopedics and traumatology</TI>
<SO>Minerva Anestesiologica</SO>
<YR>2013</YR>
<VL>79</VL>
<NO>7</NO>
<PG>778-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gearhart-2000" MODIFIED="2013-11-13 11:46:33 +0000" MODIFIED_BY="[Empty name]" NAME="Gearhart 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gearhart MM, Luchette FA, Proctor MC, Lutomski DM, Witsken C, James L, et al</AU>
<TI>The risk assessment profile score identifies trauma patients at risk for deep vein thrombosis</TI>
<SO>Surgery</SO>
<YR>2000</YR>
<VL>128</VL>
<NO>4</NO>
<PG>631-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geerts-2004" MODIFIED="2017-07-27 13:37:17 +0100" MODIFIED_BY="[Empty name]" NAME="Geerts 2004" TYPE="JOURNAL_ARTICLE">
<AU>Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al</AU>
<TI>Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126 (3 Suppl)</VL>
<PG>338S-400S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2015" MODIFIED="2017-07-28 10:20:06 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro GDT 2015" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro Guideline Development Tool (GRADEpro GDT)</TI>
<YR>Available from www.gradepro.org</YR>
<EN>2015</EN>
<PB>McMaster University (developed by Evidence Prime, Inc)</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayashino-2005" MODIFIED="2008-07-21 12:29:02 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Hayashino 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hayashino Y, Goto M, Noguchi Y, Fukui T</AU>
<TI>Ventilaton-perfusion scanning and helical CT in suspected pulmonary embolism: Meta-analysis of diagnostic performance</TI>
<SO>Radiology</SO>
<YR>2005</YR>
<VL>234</VL>
<NO>3</NO>
<PG>740-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-03-16 13:12:12 +0000" MODIFIED_BY="Cathryn  Broderick" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-2002" MODIFIED="2013-10-17 10:29:15 +0100" MODIFIED_BY="[Empty name]" NAME="Hill 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hill AB, Garber B, Dervin G, Howard A</AU>
<TI>Heparin prophylaxis for deep venous thrombosis in a patient with multiple injuries: an evidence-based approach to a clinical problem</TI>
<SO>Canadian Journal of Surgery</SO>
<YR>2002</YR>
<VL>45</VL>
<NO>4</NO>
<PG>282&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahn-2006" MODIFIED="2008-07-21 14:28:25 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Kahn 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kahn SR</AU>
<TI>The post-thrombotic syndrome: progress and pitfalls</TI>
<SO>British Journal of Haematology</SO>
<YR>2006</YR>
<VL>134</VL>
<NO>4</NO>
<PG>357&#8211;65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kakkar-1994" NAME="Kakkar 1994" TYPE="BOOK_SECTION">
<AU>Kakkar VV</AU>
<TI>Prevention of venous thromboembolism</TI>
<SO>Haemostasis and thrombosis</SO>
<YR>1994</YR>
<PG>1361-79</PG>
<EN>3rd</EN>
<ED>Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD</ED>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kujath-1991" MODIFIED="2013-12-11 14:40:12 +0000" MODIFIED_BY="[Empty name]" NAME="Kujath 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kujath P, Spannagel U, Habscheid W</AU>
<TI>Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb</TI>
<SO>Haemostasis</SO>
<YR>1991</YR>
<VL>23</VL>
<NO>suppl 1</NO>
<PG>20&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lensing-1989" MODIFIED="2008-07-21 12:29:13 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Lensing 1989" TYPE="JOURNAL_ARTICLE">
<AU>Lensing AWA, Prandoni P, Brandjes D, Huisman PM, Vigo M, Tomasella G, et al</AU>
<TI>Detection of deep-vein thrombosis by real-time B-mode ultrasonography</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<NO>6</NO>
<PG>342-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lensing-1990" MODIFIED="2008-07-21 12:29:25 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Lensing 1990" TYPE="JOURNAL_ARTICLE">
<AU>Lensing AW, Prandoni P, Buller HR, Casara D, Cogo A, ten Cate JW</AU>
<TI>Lower extremity venography with iohexol: results and complications</TI>
<SO>Radiology</SO>
<YR>1990</YR>
<VL>177</VL>
<NO>2</NO>
<PG>503-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLafferty-1998" MODIFIED="2008-07-21 14:30:48 +0100" MODIFIED_BY="Heather  Maxwell" NAME="McLafferty 1998" TYPE="JOURNAL_ARTICLE">
<AU>McLafferty RB, Moneta GL, Passman MA, Brant BB, Taylor LM Jr, Porter JM</AU>
<TI>Late clinical and hemodynamic sequelae of isolated calf vein thrombosis</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>1</NO>
<PG>50&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2017-06-20 15:17:44 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-2013" MODIFIED="2017-06-21 13:59:47 +0100" MODIFIED_BY="[Empty name]" NAME="Roberts 2013" TYPE="JOURNAL_ARTICLE">
<AU>Roberts C, Horner D, Coleman G, Maitland L, Curl-Roper Th, Smith R, Wood E, Mackway-Jones K</AU>
<TI>Guidelines in Emergency Medicine Network (GEMNet): guideline for the use of thromboprophylaxis in ambulatory trauma patients requiring temporary limb immobilisation</TI>
<SO>Emergency Medicine Journal</SO>
<YR>2013</YR>
<VL>30</VL>
<NO>11</NO>
<PG>968-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schellong-2007" MODIFIED="2013-12-11 13:29:58 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Schellong 2007" TYPE="JOURNAL_ARTICLE">
<AU>Schellong SM</AU>
<TI>Distal DVT: worth diagnosing? Yes</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>Suppl.1</NO>
<PG>51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulman-1986" MODIFIED="2008-07-21 14:33:43 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Schulman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Schulman S, Granqvist S, Juhlin-Dannfelt A, Lockner D</AU>
<TI>Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1986</YR>
<VL>219</VL>
<NO>4</NO>
<PG>349&#8211;57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vaitkus-2004" MODIFIED="2013-11-13 11:40:14 +0000" MODIFIED_BY="[Empty name]" NAME="Vaitkus 2004" TYPE="JOURNAL_ARTICLE">
<AU>Vaitkus PT</AU>
<TI>Thromboprophylaxis in immobilized medical patients</TI>
<SO>European Journal of Medical Research</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>3</NO>
<PG>131-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Adrichem-2015" MODIFIED="2017-06-21 13:58:08 +0100" MODIFIED_BY="[Empty name]" NAME="van Adrichem 2015" TYPE="JOURNAL_ARTICLE">
<AU>van Adrichem RA, van Oosten JP, Cannegieter SC, Schipper IB, Nelissen RGHH</AU>
<TI>Thromboprophylaxis for lower leg cast immobilisation and knee arthroscopy: a survey study</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>2015</YR>
<VL>73</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weitz-1997" MODIFIED="2017-06-21 13:56:16 +0100" MODIFIED_BY="[Empty name]" NAME="Weitz 1997" TYPE="JOURNAL_ARTICLE">
<AU>Weitz J</AU>
<TI>Low-molecular-weight heparins</TI>
<SO>New England Journal of Medicine</SO>
<YR>September 1997</YR>
<VL>Volume 337</VL>
<NO>10</NO>
<PG>688-98</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-06-20 14:40:35 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Testroote-2008" MODIFIED="2013-11-21 12:41:27 +0000" MODIFIED_BY="Cathryn  A Broderick" NAME="Testroote 2008" TYPE="COCHRANE_REVIEW">
<AU>Testroote M, Stigter WAH, de Visser DC, Janzing HMJ</AU>
<TI>Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-10-09 11:22:42 +0100" MODIFIED_BY="Cathryn  A Broderick"><IDENTIFIER MODIFIED="2013-10-09 11:22:42 +0100" MODIFIED_BY="Cathryn  A Broderick" TYPE="DOI" VALUE="10.1002/14651858.CD006681.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Testroote-2014" MODIFIED="2017-06-20 14:40:35 +0100" MODIFIED_BY="[Empty name]" NAME="Testroote 2014" TYPE="COCHRANE_REVIEW">
<AU>Testroote M, Stigter WAH, Janssen L, Janzing HMJ</AU>
<TI>Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-05-31 13:57:50 +0100" MODIFIED_BY="Cathryn  Broderick"><IDENTIFIER MODIFIED="2016-05-31 13:57:50 +0100" MODIFIED_BY="Cathryn  Broderick" TYPE="DOI" VALUE="10.1002/14651858.CD006681.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2017-06-20 14:52:37 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-07-28 10:25:07 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-07-28 10:14:16 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-07-28 10:08:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruntink-2017">
<CHAR_METHODS MODIFIED="2017-07-28 10:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: prospective, randomized, controlled, single-blind, multicenter study</P>
<P>Method of randomization: sealed, numbered envelopes at a ratio of 1:1:1 in blocks of 15, stratified according to centre, to one of the three study groups, by the treating physician at the ED</P>
<P>Concealment of allocation: sealed, numbered envelopes by treating physician at the ED, who was not involved in the remainder of the trial</P>
<P>Losses to follow-up: 124 (62 treatment group, 62 control group). Reasons for withdrawal: no fracture, no plaster cast, immobilization &lt; 4 weeks, indication for surgery, no duplex sonography, withdrawal of consent</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-28 10:08:50 +0100" MODIFIED_BY="[Empty name]">
<P>Country: The Netherlands</P>
<P>Number randomized: 310 (treatment group 154; control group 156)</P>
<P>Number completed study and used in analysis, reported in study publication: 186 (treatment group 92; control group 94)</P>
<P>Age mean (SD): treatment group 47.7 (16.4); control group 44.5 (17.2)</P>
<P>Sex (male/female): treatment group 39/53; control group 38/56</P>
<P>Inclusion criteria: a fracture of the ankle or foot, non-surgical treatment with immobilization in a below-knee plaster cast for a minimum of four weeks</P>
<P>Exclusion criteria: a delay between injury and the emergency department visit of more than 72 h, a known hypersensitivity to nadroparin or fondaparinux, a history of venous thromboembolism, continuous anticoagulant therapy, hypercoagulability, a bleeding tendency or disorder, pregnancy or lactation, &#8216;active&#8217; malignancy, a severe hepatic or renal impairment (deficiency of clotting factors or creatinine clearance &lt; 30 mL/min), retinopathy, previous or active bleeding from the digestive tract, a hemorrhagic stroke within the previous two months, major surgery within the previous two months, intraocular, spinal, or brain surgery within the previous year, and severe hypertension (systolic blood pressure above 180 mmHg or diastolic blood pressure above 110 mmHg)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-25 14:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: Nadroparin 2850 IE anti-Xa = 0.3 mL, given once daily</P>
<P>Control group: no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-28 10:08:50 +0100" MODIFIED_BY="[Empty name]">
<P>A venous duplex sonography of the affected leg after removal of the cast on the final day of medication administration, or earlier if thrombosis was suspected</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-07-28 10:08:51 +0100" MODIFIED_BY="[Empty name]">
<P>A second treatment group receiving Fondaparinux was not included in this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-28 10:14:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jorgensen-2002">
<CHAR_METHODS MODIFIED="2017-07-28 10:14:16 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomized, controlled, assessor-blinded, open, multicenter trial</P>
<P>Method of randomization: random numbers</P>
<P>Concealment of allocation: sealed envelopes</P>
<P>Losses to follow-up: 95; treatment group 49; control group 46. (discomfort with self-injection 18, methrorrhagia 1, refused phlebography 12, not possible to perform venography 26, miscellaneous 38</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-28 10:09:03 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Denmark</P>
<P>Number randomized: 300 (treatment group 148; control group 152)</P>
<P>Number reported, included in analysis, presented in study publication: 205 (treatment group 99; control group 106)</P>
<P>Age: adult patients &gt; 18 years (range 18 to 93)</P>
<P>Sex (male/female): treatment group 79/69; control group 93/59</P>
<P>Inclusion criteria: planned plaster immobilization of the lower leg for at least 3 weeks</P>
<P>Exclusion criteria: pregnancy, allergy to heparin or contrast media, known liver or renal impairment, uncontrolled hypertension, bleeding disorders, recent GI bleeding, or inability to perform self injection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-28 10:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: LMWH 3500 IU anti-Xa of tinzaparin (Innohep) once daily</P>
<P>Control group: no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-28 10:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>At cast removal, unilateral venography was performed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-07-28 10:09:06 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of tinzaparin relatively low, contained both operated and non-operated patients, previous DVT was not excluded, 205/300 were included in final assessment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-28 10:09:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kock-1995">
<CHAR_METHODS MODIFIED="2017-07-28 10:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomized, controlled, open trial</P>
<P>Method of randomization: randomization list stratified for varicose veins and obesity</P>
<P>Concealment of allocation: not reported</P>
<P>Losses to follow-up: 5 refused to take part, 32 excluded due to exclusion criteria, data not evaluated from 52: treatment group 21; control group 31</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-28 10:09:20 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Number randomized: 428; 5 refused to take part, 32 excluded due to exclusion criteria, data not evaluated from 52: treatment group 21; control group 31 (no final examination (12 treatment; 16 control), surgery performed before final examination (6 treatment, 12 control), changed groups (3 treatment, 3 control))</P>
<P>Number reported, included in analysis, presented in study publication: 339 (treatment group 176; control group 163)</P>
<P>Age mean (range): treatment group 34.1 years (18 to 63); control group 33.5 years (18 to 64)</P>
<P>Sex (male/female): treatment group 104/72; control group 104/59</P>
<P>Inclusion criteria: age 18 to 65, conservative treatment of injury with below-knee cast or cylinder cast</P>
<P>Exclusion criteria: previous DVT, pregnancy, clotting disorders or anticoagulation medication, bleeding, chronic venous insufficiency, contraindications for heparin prophylaxis, plaster cast after surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-28 10:09:22 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: LMWH 32 mg (certoparin; Mono-Embolex NM) once daily</P>
<P>Control group: no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-28 10:09:23 +0100" MODIFIED_BY="[Empty name]">
<P>At randomization and at plaster removal, compression ultrasound and duplex scanning were performed; suspected positive findings were confirmed by phlebography.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-11 12:38:23 +0100" MODIFIED_BY="Heather  Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kujath-1993">
<CHAR_METHODS MODIFIED="2017-07-28 10:09:28 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomized, controlled, open trial</P>
<P>Method of randomization: randomization plan "after Sachs"</P>
<P>Concealment of allocation: not reported</P>
<P>Losses to follow-up: 53 excluded post randomization (12 in treatment group interrupted prophylaxis without permission, 14 control group patients received prophylaxis, 18 lost to follow-up, 6 participants operated on before 7th day, and 3 participants had cast removed before 7th day</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Number randomized: 306, 53 excluded (12 in treatment group interrupted prophylaxis without permission, 14 control group patients received prophylaxis, 18 lost to follow-up, 6 participants operated on before 7th day, and 3 participants had cast removed before 7th day</P>
<P>Number included in analysis: 253; treatment group 126; control group 127</P>
<P>Age mean (range): treatment group 32.9 years (16 to 70); control group 35.6 years (16 to 76)</P>
<P>Sex (male/female): treatment group 69/57; control group 77/50</P>
<P>Inclusion criteria: age over 16 years, injury of the lower limb being treated conservatively, immobilization by a plaster cast applied for at least 7 days</P>
<P>Exclusion criteria: known thrombopathy, oral anticoagulation, recent brain or GI bleeding, acute pancreatitis, inflammatory heart disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-28 10:09:33 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: LMWH 36 mg heparin fraction calcium (nadroparin; Fraxiparin) once daily</P>
<P>Control group: no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-28 10:09:34 +0100" MODIFIED_BY="[Empty name]">
<P>After plaster removal, or at occurrence of symptoms, compression ultrasound to diagnose DVT; in case of doubtful or positive findings, a phlebography was carried out. In case of suspected PE, scintigraphic analysis was performed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-11 15:05:02 +0100" MODIFIED_BY="Heather  Maxwell">
<P>None of the patients were operated on.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-28 10:09:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lapidus-2007a">
<CHAR_METHODS MODIFIED="2017-07-28 10:09:38 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomized, controlled, double-blind trial</P>
<P>Method of randomization: by computer</P>
<P>Concealment of allocation: not specifically reported</P>
<P>Losses to follow-up: 4 (withdrawal of consent treatment group 2, control group 2) and excluded from efficacy analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-28 10:09:44 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Sweden</P>
<P>Number randomized: 105; treatment group 52; control group 53</P>
<P>Number reported, included in analysis 1 (all participants with negative color duplex sonography, and all participants with DVT verified by phlebography): 91; treatment group 47; control group 44</P>
<P>Number reported, included in analysis 2 (all participants with color duplex sonography for patients with multiple distal DVT or proximal DVT, and all participants with DVT verified by phlebography): 96; treatment group 49; control group 47</P>
<P>Age mean (SD): treatment group 37 years (8); control group 42 years (9)</P>
<P>Sex (male/female): treatment group 41/11; control group 42/11</P>
<P>Inclusion criteria: age 18 to 75 years, admitted for an acute (0 to 72 hours) Achilles tendon rupture, accepted for surgery</P>
<P>Exclusion criteria: inability or refusal to give informed consent, ongoing treatment with anticoagulant therapy, known allergy for contrast media, kidney disorder, recent thromboembolic event, recent surgery, known malignancy, current bleeding disorder, pregnancy, treatment with platelet inhibitors</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-28 10:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: LMWH dalteparin 5000 units sc once daily until removal of the plaster cast</P>
<P>Control group: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-28 10:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis of DVT by means of ultrasound and confirmation by venography</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-28 10:09:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lapidus-2007b">
<CHAR_METHODS MODIFIED="2017-07-28 10:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomized, controlled, double-blind trial</P>
<P>Method of randomization: not reported</P>
<P>Concealment of allocation: not reported</P>
<P>Losses to follow-up: 75 considered non-evaluable for primary analysis (35 treatment group and 40 in control group), due to: withdrawal of consent (38), technical failure of phlebography (27), refracture or resurgery (4), failure of protocol compliance (3), minor bleeding (1), inconclusive phlebography (1), never received allocated treatment due to DVT before start of treatment (1). Exclusions were evenly divided over the two groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-28 10:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Sweden</P>
<P>Number randomized: 272; treatment group 136; control group 136</P>
<P>Number reported, included in analysis 1 (assessment using phlebography): 197; treatment group 101; control group 96</P>
<P>Number reported, included in analysis 2 (assessment using phlebography plus color duplex sonography): 226; treatment group 117; control group 109</P>
<P>Age mean (SD): treatment group 49 years (14); control group 48 years (14)</P>
<P>Sex (male/female): treatment group 62/74; control group 62/74</P>
<P>Inclusion criteria: age 18 to 75 years, admitted for an acute (0 to 72 hours) ankle fracture and accepted for surgery</P>
<P>Exclusion criteria: inability or refusal to give informed consent, ongoing treatment with anticoagulant therapy, known allergy for contrast media, kidney disorder, recent thromboembolic event, recent surgery, known malignancy, current bleeding disorder, pregnancy, treatment with platelet inhibitors, multi-trauma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-28 10:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: LMWH dalteparin 5000 units sc once daily until removal of the plaster cast</P>
<P>Control group: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-28 10:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis of DVT by means of ascending venography</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-07-28 10:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>All patients treated with LMWH one week before randomization</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-28 10:10:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lassen-2002">
<CHAR_METHODS MODIFIED="2017-07-28 10:10:00 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomized, controlled, double-blind trial</P>
<P>Method of randomization: computer (blocks of four)</P>
<P>Concealment of allocation: not specifically reported</P>
<P>Losses to follow-up: 69 excluded from efficacy analysis: 2 received no injections (control group), 2 withdrew consent (treatment group), 4 withdrew because of adverse events (1 treatment, 3 control group), 61 did not have venograms that could be evaluated (31 treatment, 30 control group)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-28 10:10:08 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Denmark</P>
<P>Number randomized: 440; treatment group 217; control group 223.</P>
<P>Number reported, included in analysis, reported in study publication: 371; treatment group 183; control group 188)</P>
<P>Age median (interquartile range): treatment group 47 years (37 to 55); control group 47 years (37 to 56).</P>
<P>Sex (male/female): treatment group 112/105; control group 114/108.</P>
<P>Inclusion criteria: age 18 years or older, fracture of the leg or rupture of the Achilles tendon requiring at least 5 weeks of immobilization in a plaster cast or brace within 4 days of the injury</P>
<P>Exclusion criteria: body weight &lt; 35 kg, pre-existing VTE, systolic BP &gt; 200 mmHg or diastolic BP &gt; 110 mm Hg, cerebral vascular aneurysm, cerebral vascular accident within the preceding 3 weeks, active gastroduodenal ulcer, bacterial endocarditis, platelet count 1000,000/cu mm, previous treatment with UFH or LMWH, fibrinolytic agents, or oral anticoagulants, known hypersensitivity to contrast media, kidney disorder, MI within the preceding 3 months, multiple myeloma, pregnancy, history of drug or alcohol abuse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-28 10:10:09 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: LMWH reviparin (1750 anti-Xa units) once daily</P>
<P>Control group: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-28 10:10:10 +0100" MODIFIED_BY="[Empty name]">
<P>To diagnose DVT, venography was performed within one week after removal of the plaster. In cases of suspected PE, ventilation-perfusion lung scanning or pulmonary angiography was performed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-07-28 10:10:10 +0100" MODIFIED_BY="[Empty name]">
<P>Study contained both operated and non-operated patients; up to four days of LMWH prophylaxis was allowed before randomization.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-28 10:10:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Adrichem-2017">
<CHAR_METHODS MODIFIED="2017-07-28 10:10:15 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: multicenter, controlled, randomized, open-label with blinded outcome</P>
<P>Method of randomization: computer-generated block randomization with variable block sizes</P>
<P>Concealment of allocation: data management unit, physicians, and researchers were unaware of the randomization scheme and block sizes</P>
<P>Losses to follow-up: after randomization, 33 excluded as either failed inclusion or met exclusion criteria, 23 withdrew consent, and 28 lost to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-28 10:10:18 +0100" MODIFIED_BY="[Empty name]">
<P>Country: The Netherlands</P>
<P>Number randomized: 1519; treatment 761; control group 758</P>
<P>Number reported ,included in analysis, reported in study publication: 1435; treatment group 719; control group 716</P>
<P>Age mean (SD): treatment group 46.5 (16.5); control group 45.6 (16.4)</P>
<P>Sex (male/female): treatment group 347/372; control group 369/347</P>
<P>Inclusion criteria: patients 18 years of age or older who presented to the emergency department, and were treated for at least 1 week with casting of the lower leg (with or without surgery, before or after casting, but without multiple traumatic injuries)</P>
<P>Exclusion criteria: history of venous thromboembolism, contraindications to low molecular weight heparin therapy, pregnancy, current use of anticoagulant therapy for other indications (use of antiplatelet drugs was allowed)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-28 10:10:19 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: LMWH once daily SC injection of 2850 IU nadroparin or 2500 IU dalteparin for participants &#8804; 100 kg, or a double dose for participants weighing &gt; 100 kg (LMWH (nadroparin or dalteparin) chosen according to preference at the hospital)</P>
<P>Control group: no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-19 10:16:28 +0100" MODIFIED_BY="[Empty name]">
<P>Cumulative incidence of venous thromboembolism within 3 months of the procedure</P>
<P>Safety outcome: cumulative incidence of major bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>DVT: deep vein thrombosis<BR/>ED: emergency department<BR/>GI: gastrointestinal<BR/>Hg: mercury<BR/>IU: international units<BR/>LMWH: low molecular weight heparin<BR/>MI: myocardial infarction<BR/>PE: pulmonary embolism<BR/>sc: subcutaneous<BR/>UFH: unfractionated heparin<BR/>VTE: venous thromboembolism</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-07-28 10:25:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:14:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abelseth-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:14:32 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective incidence study, not a randomized or controlled clinical trial, operated patients without plaster immobilization and LMWH, clinical and not outpatients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ageno-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:24 +0100" MODIFIED_BY="[Empty name]">
<P>Survey on thrombosis prophylaxis by Italian orthopedic surgeons</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Armbrecht-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:26 +0100" MODIFIED_BY="[Empty name]">
<P>Patients operated on for tendon rupture, one group treated with plaster and LMWH, the other group with early functional mobilization without prophylaxis. No clinical DVTs seen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ayhan-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:26 +0100" MODIFIED_BY="[Empty name]">
<P>No LMWH used; trial was on compression stockings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bauer-1944">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:26 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breyer-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:27 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bridges-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:28 +0100" MODIFIED_BY="[Empty name]">
<P>LEAP-study (LMWH expedited Anticoagulation Program) to decrease number of inpatient days on warfarin, and total hospital days for trauma patients requiring DVT; case-control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-08 14:01:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cook-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-08 14:01:44 +0100" MODIFIED_BY="[Empty name]">
<P>Trial protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cvirn-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:29 +0100" MODIFIED_BY="[Empty name]">
<P>Patients included did not meet inclusion criteria; no lower extremity trauma or immobilization, only healthy patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eriksson-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial; comparison of fondaparinux and enoxaparin after hip-fracture surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freeark-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>Patients included did not meet inclusion criteria: no lower extremity trauma or /immobilization, only ICU patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geerts-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:31 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective study of VTE after major trauma; no prophylaxis against VTE</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geerts-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled clinical trial of LMWH and low-dose heparin; focus on major trauma, not outpatients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gehling-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective clinical study to determine incidence of DVT, no antithrombotic treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gehling-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled clinical trial; comparison of acetylsalicylic acid with LMWH in plaster immobilized trauma patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giannadakis-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:33 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective clinical study to determine incidence of DVT in selected patients, no antithrombotic treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goel-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:35 +0100" MODIFIED_BY="[Empty name]">
<P>A prospective randomized double-blind controlled trial using LMWH with saline injection as placebo in adults who had sustained an isolated fracture below the knee that required operative fixation. Study authors did not focus on immobilization of the lower leg in plaster-cast, so this study did not meet our inclusion criteria. The study authors included 238 patients, and all underwent bilateral venography for diagnosis of DVT. There was no statistically significant difference in the incidence of DVT between the patients treated with LMWH or placebo (P = 0.22). However, owing to a cessation of funding, recruitment had to be ended before the necessary sample size was established (another reason for exclusion). The study results could not categorically exclude a potentially beneficial role of LMWH treatment, and the authors recommended a further randomized controlled trial be undertaken.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenfield-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled clinical trial. Clinical trauma patients were randomized to low-dose UFH, LMWH, pneumatic compression devices, or foot pumps with or without vena caval filters.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haas-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:36 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study on the use and tolerance of LMWH in ambulatory patients; not focused on trauma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harenberg-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:37 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective cohort study to determine the clinical incidence of VTE and the tolerance to LMWH in operated and not operated surgical and orthopedic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hjelmstedt-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:37 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horner-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:38 +0100" MODIFIED_BY="[Empty name]">
<P>Patients included did not meet inclusion criteria; no lower extremity trauma or immobilization, only patients with DVT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kannus-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>Review on treatment for acute tears of the lateral ligaments of the ankle; not focused on subject of thrombosis prophylaxis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knudson-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled clinical trial; LMWH in high-risk trauma patients, compared with mechanical methods of prophylaxis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knudson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective study to identify VTE incidence and risk factors in trauma patients using the American College of Surgeons National Trauma Data Bank</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kudsk-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:40 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lassen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:40 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lim-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:41 +0100" MODIFIED_BY="[Empty name]">
<P>Patients included did not meet inclusion criteria; no lower extremity trauma or immobilization, only ICU patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lippert-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:41 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marlovits-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:41 +0100" MODIFIED_BY="[Empty name]">
<P>This study focused on prolonged thrombosis prophylaxis after arthroscopic surgery rather than immobilization of the lower leg after trauma, and was excluded for that reason.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinole-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:41 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Micheli-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:42 +0100" MODIFIED_BY="[Empty name]">
<P>Case report, expert opinion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:25:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00843492">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>The purpose of this ongoing study sponsored by GlaxoSmithKline is to evaluate the efficacy and safety of fondaparinux in comparison with a LMWH (nadroparin) in preventing VTE in patients with leg injuries below the knee that require a cast or other type of immobilization, but not surgery. This study does not meet our inclusion criteria (LMWH versus placebo or no prophylaxis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nesheiwat-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:42 +0100" MODIFIED_BY="[Empty name]">
<P>Case report and literature review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reilmann-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:42 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reilmann-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:42 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samama-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:43 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment protocol did not meet inclusion criteria; comparing fondaparinux with LMWH</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-19 15:11:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saragas-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-19 15:11:38 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schultz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:43 +0100" MODIFIED_BY="[Empty name]">
<P>Focus on multiple trauma patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Selby-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>In this study (known as the D-KAF trial), consecutive patients with isolated fractures of the distal leg requiring surgery were randomized to dalteparin 5000 IU or placebo once daily SC. Patients were screened using proximal ultrasound (only of the upper leg, not the calf) at day 14. The researchers were interested in clinically important venous thromboembolism (CIVTE). The study authors found that the overall incidence of CIVTE was so low (1.9%; 95% CI 0.7 to 4.7%), with no observed differences between dalteparin and placebo, that recruitment was stopped early. For this reason, we did not include this study in our meta-analysis. However, the study demonstrated the large discrepancy between trials that use venographic outcomes (all DVTs) and CIVTE.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spieler-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warot-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized or controlled clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-28 10:10:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-28 10:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Cohort of 515 patients with plaster immobilization of the lower leg treated with LMWH; no comparison</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-21 14:41:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zagrodnick-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-21 14:41:01 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective data and prospective study to evaluate self-injection of UFH and LMWH.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CIVTE: clinically important venous thromboembolism<BR/>DVT: deep vein thrombosis<BR/>HIT: heparin-induced thrombocytopenia<BR/>ICU: intensive care unit<BR/>LMWH: low molecular weight heparin<BR/>SC: subcutaneous<BR/>UFH: unfractionated heparin<BR/>VTE: venous thromboembolism</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-06-08 14:36:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-06-08 14:37:08 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-07-28 10:10:23 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-07-28 10:09:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:08:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruntink-2017">
<DESCRIPTION>
<P>"..patients were enrolled and randomly assigned (by use of sealed, numbered envelopes, at a ratio of 1:1:1 in blocks of 15, stratified according to centre) to one of the three study groups, by the treating physician at the ED."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 14:03:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorgensen-2002">
<DESCRIPTION>
<P>Random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kock-1995">
<DESCRIPTION>
<P>Randomization with lists stratified for varicose veins and obesity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-20 15:15:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kujath-1993">
<DESCRIPTION>
<P>"patients were allocated to two groups according to a random plan after Sachs". Unclear method of randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapidus-2007a">
<DESCRIPTION>
<P>Randomization by computer, no further information provided. However, patients were not included when study personnel were off duty</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapidus-2007b">
<DESCRIPTION>
<P>Method of randomization was not described. Patients were not included when study personnel were off duty.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-20 15:43:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lassen-2002">
<DESCRIPTION>
<P>" randomization was performed by computer in blocks of four"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-14 12:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Adrichem-2017">
<DESCRIPTION>
<P>Block randomization with variable block sizes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-07-28 10:10:19 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:08:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruntink-2017">
<DESCRIPTION>
<P>Sealed, numbered envelopes from treating physician at the ED, who was not involved in the remainder of the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorgensen-2002">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kock-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kujath-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-19 15:14:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapidus-2007a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapidus-2007b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-19 15:15:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lassen-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:10:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Adrichem-2017">
<DESCRIPTION>
<P>"To ensure concealment of treatment assignment the data management unit, physicians, and researchers were unaware of the randomization scheme and block sizes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-05-31 13:52:54 +0100" MODIFIED_BY="Cathryn  Broderick" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-07-28 10:10:21 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-28 10:08:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bruntink-2017">
<DESCRIPTION>
<P>Reported as a single-blind study. Blinding of participants was not reported, blinding of personnel other than the ultrasound technician was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-28 10:09:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jorgensen-2002">
<DESCRIPTION>
<P>Patients were either treated with Tinzaparin, or received no treatment. A placebo was not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-28 10:09:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kock-1995">
<DESCRIPTION>
<P>Open study format, in which no placebo was used. The treatment group received injections of LMWH, the control group received none. Blinding of personnel was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-28 10:09:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kujath-1993">
<DESCRIPTION>
<P>Blinding of personnel was not reported. "Patients of group II did not receive heparin". A placebo was not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-28 10:09:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapidus-2007a">
<DESCRIPTION>
<P>Study described as double-blind. Each patient received a box containing 45 prefilled syringes with either Dalteparin or placebo. Syringes of both groups were identical. Blinding of personnel was not explicitly described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-28 10:09:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapidus-2007b">
<DESCRIPTION>
<P>Study described as double-blind. Patients were blinded by using identical prefilled syringes. Blinding of personnel was not explicitly described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-28 10:10:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lassen-2002">
<DESCRIPTION>
<P>Described as double-blind study. Patients received identical prefilled syringes in both groups. Personnel were blinded until database was locked and results were revealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-28 10:10:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-Adrichem-2017">
<DESCRIPTION>
<P>Open-label trial, participants and personnel were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-07-28 10:10:21 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-04-19 18:28:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruntink-2017">
<DESCRIPTION>
<P>The ultrasound technician who assessed the primary outcome was blinded to the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-08-08 14:07:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorgensen-2002">
<DESCRIPTION>
<P>' assessor-blinded'; two radiologists, unaware of treatment, independently assessed the venograms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-07-28 10:09:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kock-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-07-28 10:09:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kujath-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-08-08 15:27:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapidus-2007a">
<DESCRIPTION>
<P>"evaluation was carried out by an experienced independent radiologist blinded to the randomization and previous phlebographic findings"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-07-28 10:09:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapidus-2007b">
<DESCRIPTION>
<P>Outcome measures were assessed by a radiologist blinded to randomization and previous imaging findings.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-07-28 10:10:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lassen-2002">
<DESCRIPTION>
<P>Venograms were evaluated by experienced radiologists, blinded to the treatment assignments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-07-28 10:10:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Adrichem-2017">
<DESCRIPTION>
<P>All outcomes were assessed by an independent committee whose members were unaware of assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-07-28 10:10:22 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-28 10:08:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bruntink-2017">
<DESCRIPTION>
<P>124/310 participants were excluded from the analysis after randomization, 62 in both treatment and control group. Reasons for withdrawal: no fracture, no plaster cast, immobilization &lt; 4 weeks, indication for surgery, no duplex sonography, withdrawal of consent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-28 10:09:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jorgensen-2002">
<DESCRIPTION>
<P>95 out of 300 patients were lost to follow-up. They were evenly divided between groups (treatment group = 49, no treatment group = 46). Reasons for losses to follow-up were discomfort with self-injection (18), metrorrhagia (1), refusal of phlebography (12), not possible to perform venography (26), and miscellaneous (38). Reasons varied between the two groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-19 15:11:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kock-1995">
<DESCRIPTION>
<P>Data of 52 out of 428 randomized participants could not be evaluated, reasons provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-28 10:09:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kujath-1993">
<DESCRIPTION>
<P>53 out of 306 patients were excluded for various reasons. It is unclear how those were divided over the two groups. Reasons for exclusion were patient interruption of prophylaxis, patients receiving prophylaxis from co-treating practitioner, change of treating physician, surgery before 7th day.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-28 10:09:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapidus-2007a">
<DESCRIPTION>
<P>4 patients were lost to follow-up, evenly divided between the two groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-28 10:09:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapidus-2007b">
<DESCRIPTION>
<P>75 out of 272 patients were considered non-evaluable for primary analysis due to withdrawal of consent (38), technical failure of phlebography (27), refracture or resurgery (4), failure of protocol compliance (3), minor bleeding (1), inconclusive phlebography (1), never received allocated treatment due to DVT before start of treatment (1). Exclusions were evenly divided over the two groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-28 10:10:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lassen-2002">
<DESCRIPTION>
<P>69/440 participants were excluded, divided evenly over both groups. Exclusion was mainly due to the technical impossibility to perform a venogram in the patient (61 participants).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-07-28 10:10:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Adrichem-2017">
<DESCRIPTION>
<P>84/1519 participants lost to follow-up, withdrew consent, or failed inclusion criteria and were not included in the analysis. 93/719 patients did not adhere to the LMWH trial regimen.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-07-28 10:10:23 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:08:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruntink-2017">
<DESCRIPTION>
<P>Primary and secondary outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jorgensen-2002">
<DESCRIPTION>
<P>Primary and secondary outcomes were not described in methods. Therefore, it was unclear whether all assessed outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kock-1995">
<DESCRIPTION>
<P>Primary and secondary outcomes were not described. Therefore, it was unclear whether all assessed outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kujath-1993">
<DESCRIPTION>
<P>Primary outcomes were reported. However, nothing was reported on possible adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapidus-2007a">
<DESCRIPTION>
<P>Outcome measures were reported, as well as any adverse event.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 20:22:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapidus-2007b">
<DESCRIPTION>
<P>Primary efficacy, secondary efficacy and any adverse events were assessed and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:10:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lassen-2002">
<DESCRIPTION>
<P>All outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:10:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Adrichem-2017">
<DESCRIPTION>
<P>Primary and secondary effective. as well as safety outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-07-28 10:10:23 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 20:15:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruntink-2017">
<DESCRIPTION>
<P>No other bias was detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorgensen-2002">
<DESCRIPTION>
<P>No other bias was detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kock-1995">
<DESCRIPTION>
<P>No other bias was detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 20:15:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kujath-1993">
<DESCRIPTION>
<P>No other bias was detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:09:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapidus-2007a">
<DESCRIPTION>
<P>No other bias was detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-23 20:16:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapidus-2007b">
<DESCRIPTION>
<P>No other bias was detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:10:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lassen-2002">
<DESCRIPTION>
<P>No other bias was detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-28 10:10:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Adrichem-2017">
<DESCRIPTION>
<P>No other bias was detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]">Low molecular weight heparin compared to no prophylaxis or placebo in prevention of venous thromboembolism in patients with lower-limb immobilization</TITLE>
<TABLE COLS="7" ROWS="18">
<TR>
<TH ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Low molecular weight heparin compared to no prophylaxis or placebo in prevention of venous thromboembolism in patients with lower-limb immobilization</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>prevention of venous thromboembolism in patients with lower-limb immobilization<BR/>
<B>Setting: </B>ambulatory setting<BR/>
<B>Intervention: </B>low molecular weight heparin<BR/>
<B>Comparison: </B>no prophylaxis or placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with no prophylaxis or placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with low molecular weight heparin</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Deep venous thrombosis</P>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>OR 0.45<BR/>(0.33 to 0.61)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>1676<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>174 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>87 per 1000<BR/>(65 to 114)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Pulmonary embolism</P>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>OR 0.50<BR/>(0.17 to 1.47)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>2517<BR/>(5 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>7 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>4 per 1000<BR/>(1 to 10)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Symptomatic venous thromboembolism</P>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>OR 0.40<BR/>(0.21 to 0.76)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>2924<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>21 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>9 per 1000<BR/>(5 to 16)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Mortality due to pulmonary embolism</P>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>3111<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>No mortality due to pulmonary embolism was reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>see comment</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>see comment</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Mortality due to other causes</P>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>OR 0.33</P>
<P>(0.01 to 8.15)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>3111<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>4</SUP>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>One death (in no prophylaxis/placebo group) was reported in the included studies</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>1 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000</P>
<P>(0 to 5)</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Adverse outcomes</P>
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>OR 2.01<BR/>(0.83 to 4.86)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>3178<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>40 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>78 per 1000<BR/>(34 to 170)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*We calculated the assumed risk of the no prophylaxis or placebo group from the average risk in the no prophylaxis or placebo groups (i.e. the number of participants with events divided by total number of participants of the no prophylaxis or placebo group included in the meta-analysis). The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> confidence interval; <B>OR:</B> odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded by one level as 3 out of 7 studies showed considerable risk of bias<BR/>
<SUP>2</SUP> Downgraded by two levels as 2 out of 5 studies showed considerable risk of bias, and imprecision of pooled results<BR/>
<SUP>3</SUP> Downgraded by two levels as 3 out of 6 studies showed considerable risk of bias, and imprecision of pooled results<BR/>
<SUP>4</SUP> Downgraded by two levels due to the low number of events, and imprecision of pooled results<BR/>
<SUP>5</SUP> Downgraded by two levels as 4 out of 8 studies showed considerable risk of bias, and imprecision of pooled results</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-07-27 15:11:34 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-07-27 15:11:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Low molecular weight heparin versus no prophylaxis or placebo</NAME>
<DICH_OUTCOME CHI2="8.111763128865519" CI_END="0.6110509189390424" CI_START="0.3292614319161353" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.44854821429088243" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="145" I2="26.033343125502018" I2_Q="100.0" ID="CMP-001.01" LOG_CI_END="-0.21392259844344966" LOG_CI_START="-0.4824591374537861" LOG_EFFECT_SIZE="-0.3481908679486179" METHOD="MH" MODIFIED="2017-07-27 15:11:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23002916715561883" P_Q="0.0" P_Z="3.721622337936117E-7" Q="4.9538001392651575E-31" RANDOM="NO" SCALE="394.2422499741934" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="842" TOTAL_2="834" WEIGHT="100.00000000000001" Z="5.082671903347682">
<NAME>Deep venous thrombosis: regardless of type of plaster, whether operated or not</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7789253547942142" CI_START="0.03609524102082492" EFFECT_SIZE="0.16767676767676767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10850415921350566" LOG_CI_START="-1.442550053901484" LOG_EFFECT_SIZE="-0.7755271065574948" MODIFIED="2017-07-27 15:11:28 +0100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.7836251621733993" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="0.6140683947912864" WEIGHT="8.479957147282239"/>
<DICH_DATA CI_END="1.256316195809937" CI_START="0.24018250072357233" EFFECT_SIZE="0.5493133583021224" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.09909895851985405" LOG_CI_START="-0.6194586377159546" LOG_EFFECT_SIZE="-0.26017983959805024" MODIFIED="2017-07-27 15:11:34 +0100" MODIFIED_BY="[Empty name]" ORDER="35295" O_E="0.0" SE="0.42208428894638056" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="99" TOTAL_2="106" VAR="0.1781551469753717" WEIGHT="12.45030692825811"/>
<DICH_DATA CI_END="1.0433876526945018" CI_START="0.003348968426999854" EFFECT_SIZE="0.0591123701605288" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.018445693035797486" LOG_CI_START="-2.475088946829908" LOG_EFFECT_SIZE="-1.2283216268970554" MODIFIED="2017-07-27 15:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="35296" O_E="0.0" SE="1.4647145906526513" STUDY_ID="STD-Kock-1995" TOTAL_1="176" TOTAL_2="163" VAR="2.145388832070764" WEIGHT="6.184762134278162"/>
<DICH_DATA CI_END="0.648778377914495" CI_START="0.09817858808653343" EFFECT_SIZE="0.2523809523809524" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="21" LOG_CI_END="-0.18790363245426514" LOG_CI_START="-1.0079832178119954" LOG_EFFECT_SIZE="-0.5979434251331303" MODIFIED="2017-07-27 15:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="35297" O_E="0.0" SE="0.4817188078985484" STUDY_ID="STD-Kujath-1993" TOTAL_1="126" TOTAL_2="127" VAR="0.23205300988319855" WEIGHT="15.869068208065361"/>
<DICH_DATA CI_END="1.9479422802664461" CI_START="0.3758844841920189" EFFECT_SIZE="0.8556876061120543" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.28957608409641455" LOG_CI_START="-0.4249456007795673" LOG_EFFECT_SIZE="-0.06768475834157636" ORDER="35298" O_E="0.0" SE="0.4197135746355349" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="0.1761594847333387" WEIGHT="9.774970805064799"/>
<DICH_DATA CI_END="1.0420667976195155" CI_START="0.3109751746554855" EFFECT_SIZE="0.5692599620493358" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.01789555860626848" LOG_CI_START="-0.5072742795920369" LOG_EFFECT_SIZE="-0.2446893604928842" ORDER="35299" O_E="0.0" SE="0.30848736259030995" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="117" TOTAL_2="109" VAR="0.09516445287792535" WEIGHT="22.290757830273524"/>
<DICH_DATA CI_END="0.8319116653796441" CI_START="0.2409080018149956" EFFECT_SIZE="0.4476764199655766" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="35" LOG_CI_END="-0.07992278581848934" LOG_CI_START="-0.6181487745704266" LOG_EFFECT_SIZE="-0.34903578019445797" ORDER="35300" O_E="0.0" SE="0.3161566100545009" STUDY_ID="STD-Lassen-2002" TOTAL_1="183" TOTAL_2="188" VAR="0.09995500208115375" WEIGHT="24.95017694677782"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.2819280671904645" CI_END="0.7162245656204982" CI_START="0.3371283362857246" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4913853846163969" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="93" I2="20.406602136783064" I2_Q="100.00000000000001" ID="CMP-001.02" LOG_CI_END="-0.1449507873028049" LOG_CI_START="-0.4722047426575225" LOG_EFFECT_SIZE="-0.3085777649801637" METHOD="MH" MODIFIED="2017-07-26 17:43:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.27974466161854183" P_Q="0.0" P_Z="2.1883336866589887E-4" Q="3.3356113803255727E-31" RANDOM="NO" SCALE="343.96" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="557" TOTAL_2="523" WEIGHT="100.00000000000001" Z="3.696219989979519">
<NAME>Deep venous thrombosis: in below-knee cast, whether operated or not</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7789253547942142" CI_START="0.03609524102082492" EFFECT_SIZE="0.16767676767676767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10850415921350566" LOG_CI_START="-1.442550053901484" LOG_EFFECT_SIZE="-0.7755271065574948" MODIFIED="2017-04-19 18:01:58 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.7836251621733993" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="0.6140683947912864" WEIGHT="13.414085745316589"/>
<DICH_DATA CI_END="1.256316195809937" CI_START="0.24018250072357233" EFFECT_SIZE="0.5493133583021224" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.09909895851985405" LOG_CI_START="-0.6194586377159546" LOG_EFFECT_SIZE="-0.26017983959805024" ORDER="35301" O_E="0.0" SE="0.42208428894638056" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="99" TOTAL_2="106" VAR="0.1781551469753717" WEIGHT="19.694614228644863"/>
<DICH_DATA CI_END="1.4635008124987705" CI_START="0.004392649417691167" EFFECT_SIZE="0.08017883755588674" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.16539296787922972" LOG_CI_START="-2.3572734568844353" LOG_EFFECT_SIZE="-1.095940244502603" ORDER="35302" O_E="0.0" SE="1.4818267453063736" STUDY_ID="STD-Kock-1995" TOTAL_1="152" TOTAL_2="139" VAR="2.19581050310528" WEIGHT="7.214458516607984"/>
<DICH_DATA CI_END="1.9479422802664461" CI_START="0.3758844841920189" EFFECT_SIZE="0.8556876061120543" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.28957608409641455" LOG_CI_START="-0.4249456007795673" LOG_EFFECT_SIZE="-0.06768475834157636" ORDER="35303" O_E="0.0" SE="0.4197135746355349" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="0.1761594847333387" WEIGHT="15.462613107559068"/>
<DICH_DATA CI_END="1.0420667976195155" CI_START="0.3109751746554855" EFFECT_SIZE="0.5692599620493358" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.01789555860626848" LOG_CI_START="-0.5072742795920369" LOG_EFFECT_SIZE="-0.2446893604928842" ORDER="35304" O_E="0.0" SE="0.30848736259030995" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="117" TOTAL_2="109" VAR="0.09516445287792535" WEIGHT="35.260807533586025"/>
<DICH_DATA CI_END="1.0703165706813098" CI_START="0.05582748885380452" EFFECT_SIZE="0.24444444444444444" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.029512249242091546" LOG_CI_START="-1.2531519064763288" LOG_EFFECT_SIZE="-0.6118198286171187" ORDER="35305" O_E="0.0" SE="0.753443274358971" STUDY_ID="STD-Lassen-2002" TOTAL_1="48" TOTAL_2="28" VAR="0.5676767676767676" WEIGHT="8.953420868285475"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.977743113238268" CI_END="0.5348836652631614" CI_START="0.18063317186446332" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3108339316017071" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="55" I2="19.642297543197195" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.27174066476042114" LOG_CI_START="-0.7432024919250456" LOG_EFFECT_SIZE="-0.5074715783427334" METHOD="MH" MODIFIED="2017-07-26 17:43:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2895888897749175" P_Q="1.0" P_Z="2.450317013980163E-5" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="492" TOTAL_2="482" WEIGHT="100.0" Z="4.219327883706486">
<NAME>Deep venous thrombosis: conservative treatment (i.e. non-operated patients)</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7789253547942142" CI_START="0.03609524102082492" EFFECT_SIZE="0.16767676767676767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10850415921350566" LOG_CI_START="-1.442550053901484" LOG_EFFECT_SIZE="-0.7755271065574948" MODIFIED="2017-04-19 18:08:51 +0100" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.7836251621733993" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="0.6140683947912864" WEIGHT="20.245400015114363"/>
<DICH_DATA CI_END="7.749402111427406" CI_START="0.05040711455971259" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8892681967354253" LOG_CI_START="-1.297508162047275" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="35309" O_E="0.0" SE="1.284523257866513" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="13" TOTAL_2="17" VAR="1.65" WEIGHT="3.042944971968705"/>
<DICH_DATA CI_END="1.0433876526945018" CI_START="0.003348968426999854" EFFECT_SIZE="0.0591123701605288" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.018445693035797486" LOG_CI_START="-2.475088946829908" LOG_EFFECT_SIZE="-1.2283216268970554" ORDER="35310" O_E="0.0" SE="1.4647145906526513" STUDY_ID="STD-Kock-1995" TOTAL_1="176" TOTAL_2="163" VAR="2.145388832070764" WEIGHT="14.765756622593742"/>
<DICH_DATA CI_END="0.648778377914495" CI_START="0.09817858808653343" EFFECT_SIZE="0.2523809523809524" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="21" LOG_CI_END="-0.18790363245426514" LOG_CI_START="-1.0079832178119954" LOG_EFFECT_SIZE="-0.5979434251331303" ORDER="35311" O_E="0.0" SE="0.4817188078985484" STUDY_ID="STD-Kujath-1993" TOTAL_1="126" TOTAL_2="127" VAR="0.23205300988319855" WEIGHT="37.88646901858268"/>
<DICH_DATA CI_END="1.5319926471468088" CI_START="0.2657751221183246" EFFECT_SIZE="0.638095238095238" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.18525668088977681" LOG_CI_START="-0.5754856736280002" LOG_EFFECT_SIZE="-0.19511449636911168" ORDER="35312" O_E="0.0" SE="0.4468638247791301" STUDY_ID="STD-Lassen-2002" TOTAL_1="85" TOTAL_2="81" VAR="0.1996872778962331" WEIGHT="24.05942937174051"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6505508319549387" CI_END="0.7968414825400311" CI_START="0.3718075451494568" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5443084378332406" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.09862806518515181" LOG_CI_START="-0.42968180126792466" LOG_EFFECT_SIZE="-0.2641549332265382" METHOD="MH" MODIFIED="2017-07-26 17:43:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.44869622766890405" P_Q="1.0" P_Z="0.0017612281269008324" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="349" TOTAL_2="350" WEIGHT="100.0" Z="3.1277952732915213">
<NAME>Deep venous thrombosis: operated patients</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2820526847081504" CI_START="0.22182140461694938" EFFECT_SIZE="0.5332792207792207" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.10790587245884725" LOG_CI_START="-0.653996548996099" LOG_EFFECT_SIZE="-0.2730453382686259" ORDER="35313" O_E="0.0" SE="0.4475452538404473" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="86" TOTAL_2="89" VAR="0.2002967542351104" WEIGHT="19.275523558855916"/>
<DICH_DATA CI_END="1.9479422802664461" CI_START="0.3758844841920189" EFFECT_SIZE="0.8556876061120543" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.28957608409641455" LOG_CI_START="-0.4249456007795673" LOG_EFFECT_SIZE="-0.06768475834157636" ORDER="35314" O_E="0.0" SE="0.4197135746355349" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="0.1761594847333387" WEIGHT="16.79877393490491"/>
<DICH_DATA CI_END="1.0420667976195155" CI_START="0.3109751746554855" EFFECT_SIZE="0.5692599620493358" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.01789555860626848" LOG_CI_START="-0.5072742795920369" LOG_EFFECT_SIZE="-0.2446893604928842" ORDER="35315" O_E="0.0" SE="0.30848736259030995" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="117" TOTAL_2="109" VAR="0.09516445287792535" WEIGHT="38.30777698430109"/>
<DICH_DATA CI_END="0.7695111360194752" CI_START="0.12578131611904378" EFFECT_SIZE="0.3111111111111111" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.11378509087238058" LOG_CI_START="-0.9003838653218308" LOG_EFFECT_SIZE="-0.5070844780971057" ORDER="35316" O_E="0.0" SE="0.46205201383833777" STUDY_ID="STD-Lassen-2002" TOTAL_1="97" TOTAL_2="105" VAR="0.21349206349206346" WEIGHT="25.617925521938066"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.444014149898814" CI_END="0.6998315624451275" CI_START="0.333893521641199" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4833934473495336" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="97" I2="0.0" I2_Q="100.0" ID="CMP-001.05" LOG_CI_END="-0.15500647470443074" LOG_CI_START="-0.4763920072492335" LOG_EFFECT_SIZE="-0.3156992409768321" METHOD="MH" MODIFIED="2017-07-26 17:43:05 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.48740918162941804" P_Q="0.0" P_Z="1.1784205243028966E-4" Q="3.4585384650007215E-31" RANDOM="NO" SCALE="164.8" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="493" TOTAL_2="510" WEIGHT="99.99999999999999" Z="3.8505724720198127">
<NAME>Deep venous thrombosis: fractures</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7789253547942142" CI_START="0.03609524102082492" EFFECT_SIZE="0.16767676767676767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10850415921350566" LOG_CI_START="-1.442550053901484" LOG_EFFECT_SIZE="-0.7755271065574948" MODIFIED="2017-04-19 18:09:34 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.7836251621733993" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="0.6140683947912864" WEIGHT="12.713509936639756"/>
<DICH_DATA CI_END="2.219976239326819" CI_START="0.3063053200743165" EFFECT_SIZE="0.8246153846153846" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.34634832616934497" LOG_CI_START="-0.513845460069516" LOG_EFFECT_SIZE="-0.08374856695008555" ORDER="35317" O_E="0.0" SE="0.5052820880646214" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="73" TOTAL_2="77" VAR="0.25530998851894376" WEIGHT="10.350594958516812"/>
<DICH_DATA CI_END="3.6444001920454006" CI_START="0.007821304485471706" EFFECT_SIZE="0.16883116883116883" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5616260608514831" LOG_CI_START="-2.106720806582773" LOG_EFFECT_SIZE="-0.7725473728656451" ORDER="35318" O_E="0.0" SE="1.5674001584609005" STUDY_ID="STD-Kock-1995" TOTAL_1="38" TOTAL_2="34" VAR="2.4567432567432563" WEIGHT="3.1067924056878686"/>
<DICH_DATA CI_END="0.9787647364544005" CI_START="0.08039846146887142" EFFECT_SIZE="0.2805194805194805" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.009321686070501578" LOG_CI_START="-1.0947522619726004" LOG_EFFECT_SIZE="-0.552036974021551" ORDER="35319" O_E="0.0" SE="0.6375872932528976" STUDY_ID="STD-Kujath-1993" TOTAL_1="39" TOTAL_2="38" VAR="0.40651755651755656" WEIGHT="11.942994182904014"/>
<DICH_DATA CI_END="1.0420667976195155" CI_START="0.3109751746554855" EFFECT_SIZE="0.5692599620493358" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.01789555860626848" LOG_CI_START="-0.5072742795920369" LOG_EFFECT_SIZE="-0.2446893604928842" ORDER="35320" O_E="0.0" SE="0.30848736259030995" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="117" TOTAL_2="109" VAR="0.09516445287792535" WEIGHT="33.41924566932964"/>
<DICH_DATA CI_END="1.0290732238363605" CI_START="0.26171627231886796" EFFECT_SIZE="0.5189655172413793" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" LOG_CI_END="0.012446278141107936" LOG_CI_START="-0.582169274079296" LOG_EFFECT_SIZE="-0.28486149796909394" ORDER="35321" O_E="0.0" SE="0.3492801187687191" STUDY_ID="STD-Lassen-2002" TOTAL_1="134" TOTAL_2="158" VAR="0.12199660136709053" WEIGHT="28.4668628469219"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.313098525090145" CI_END="0.6779547451480135" CI_START="0.22054603086012645" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.38667845575514415" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="48" I2="36.63967093016525" I2_Q="100.0" ID="CMP-001.06" LOG_CI_END="-0.1687992952014505" LOG_CI_START="-0.6565007537597801" LOG_EFFECT_SIZE="-0.4126500244806152" METHOD="MH" MODIFIED="2017-07-26 17:42:55 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.1769544951917208" P_Q="0.0" P_Z="9.10880719588891E-4" Q="1.5018866146758535E-31" RANDOM="NO" SCALE="416.98" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="343" TOTAL_2="315" WEIGHT="100.0" Z="3.3166978363869166">
<NAME>Deep venous thrombosis: soft-tissue injuries</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1464224116196369" CI_START="0.0417399049556232" EFFECT_SIZE="0.21875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05934466757386563" LOG_CI_START="-1.379448544185164" LOG_EFFECT_SIZE="-0.6600519383056491" ORDER="35322" O_E="0.0" SE="0.8451542547285166" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="26" TOTAL_2="29" VAR="0.7142857142857142" WEIGHT="16.76819265480569"/>
<DICH_DATA CI_END="1.4485785024179438" CI_START="0.004335156755576802" EFFECT_SIZE="0.07924528301886792" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1609420357794158" LOG_CI_START="-2.362995194185193" LOG_EFFECT_SIZE="-1.1010265792028886" ORDER="35323" O_E="0.0" SE="1.4825732225719952" STUDY_ID="STD-Kock-1995" TOTAL_1="132" TOTAL_2="120" VAR="2.198023360287511" WEIGHT="13.781375529966999"/>
<DICH_DATA CI_END="0.8747044452835819" CI_START="0.03950162745971429" EFFECT_SIZE="0.18588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.05813866636679004" LOG_CI_START="-1.4033850111529502" LOG_EFFECT_SIZE="-0.7307618387598701" ORDER="35324" O_E="0.0" SE="0.7902043620041933" STUDY_ID="STD-Kujath-1993" TOTAL_1="87" TOTAL_2="89" VAR="0.6244229337304541" WEIGHT="23.198183197566465"/>
<DICH_DATA CI_END="1.9479422802664461" CI_START="0.3758844841920189" EFFECT_SIZE="0.8556876061120543" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.28957608409641455" LOG_CI_START="-0.4249456007795673" LOG_EFFECT_SIZE="-0.06768475834157636" ORDER="35325" O_E="0.0" SE="0.4197135746355349" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="0.1761594847333387" WEIGHT="29.47078998765356"/>
<DICH_DATA CI_END="1.1358954910448682" CI_START="0.05991125996469219" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.05533837560878271" LOG_CI_START="-1.222491546876681" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="35326" O_E="0.0" SE="0.7506036218280919" STUDY_ID="STD-Lassen-2002" TOTAL_1="49" TOTAL_2="30" VAR="0.5634057971014492" WEIGHT="16.78145863000728"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0608703424900483" CI_END="0.8850138854213208" CI_START="0.4228410187133203" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6117353781554448" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.05304991538742701" LOG_CI_START="-0.37382288953687465" LOG_EFFECT_SIZE="-0.21343640246215084" METHOD="MH" MODIFIED="2017-07-26 17:42:17 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5476911615899454" P_Q="1.0" P_Z="0.009100711305156727" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="608" TOTAL_2="600" WEIGHT="100.0" Z="2.6082475490638655">
<NAME>Deep venous thrombosis: distal segment</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.35513480538303" CI_START="0.2553404723066438" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.13198249987604693" LOG_CI_START="-0.5928803426325948" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="35327" O_E="0.0" SE="0.4257880218185151" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="99" TOTAL_2="106" VAR="0.18129543952412427" WEIGHT="20.129714233161707"/>
<DICH_DATA CI_END="1.8796318679826531" CI_START="0.00536381927823702" EFFECT_SIZE="0.10040919106074914" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2740727996046331" LOG_CI_START="-2.270525863144566" LOG_EFFECT_SIZE="-0.9982265317699663" ORDER="35328" O_E="0.0" SE="1.4947098504654053" STUDY_ID="STD-Kock-1995" TOTAL_1="176" TOTAL_2="163" VAR="2.2341575370783144" WEIGHT="6.352656708499321"/>
<DICH_DATA CI_END="2.3905047188565645" CI_START="0.4431917864573498" EFFECT_SIZE="1.029296875" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.378489605330007" LOG_CI_START="-0.35340829685657527" LOG_EFFECT_SIZE="0.012540654236715852" ORDER="35329" O_E="0.0" SE="0.42992045069744445" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="0.18483159392789375" WEIGHT="14.546257476265783"/>
<DICH_DATA CI_END="1.2183655311312267" CI_START="0.30255488977707173" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.08577760384468242" LOG_CI_START="-0.5191958237725731" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="35330" O_E="0.0" SE="0.35536438604913995" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="101" TOTAL_2="96" VAR="0.12628384687208216" WEIGHT="27.91109302552521"/>
<DICH_DATA CI_END="1.0754732769810234" CI_START="0.27125529838817836" EFFECT_SIZE="0.5401183431952663" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.03159962364596668" LOG_CI_START="-0.5666217700529973" LOG_EFFECT_SIZE="-0.2675110732035153" ORDER="35331" O_E="0.0" SE="0.3513982079024286" STUDY_ID="STD-Lassen-2002" TOTAL_1="183" TOTAL_2="188" VAR="0.12348070051703842" WEIGHT="31.06027855654798"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0451688079053767" CI_END="0.905000444973244" CI_START="0.18573983493957585" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4099934551545586" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.04335120725957356" LOG_CI_START="-0.731094944729965" LOG_EFFECT_SIZE="-0.38722307599476924" METHOD="MH" MODIFIED="2017-07-26 17:42:01 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5502952506126457" P_Q="1.0" P_Z="0.027310388615038223" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="614" TOTAL_2="603" WEIGHT="100.0" Z="2.2070525446703555">
<NAME>Deep venous thrombosis: proximal segment</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.777986084068601" CI_START="0.014230539342897369" EFFECT_SIZE="0.35343383584589616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9433948880130548" LOG_CI_START="-1.8467786396764077" LOG_EFFECT_SIZE="-0.4516918758316764" ORDER="35332" O_E="0.0" SE="1.6389617417465026" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="99" TOTAL_2="106" VAR="2.6861955909087296" WEIGHT="6.929838322108544"/>
<DICH_DATA CI_END="2.534385103021765" CI_START="0.006658738608928851" EFFECT_SIZE="0.12990692027519224" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40387260715748236" LOG_CI_START="-2.176608033151897" LOG_EFFECT_SIZE="-0.8863677129972073" ORDER="35333" O_E="0.0" SE="1.5157871017029088" STUDY_ID="STD-Kock-1995" TOTAL_1="176" TOTAL_2="163" VAR="2.297610537688904" WEIGHT="17.411551954511335"/>
<DICH_DATA CI_END="3.047190762873341" CI_START="0.030639433102910375" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48389964315275297" LOG_CI_START="-1.5137192743708776" LOG_EFFECT_SIZE="-0.5149098156090622" ORDER="35334" O_E="0.0" SE="1.1734112405264998" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="1.3768939393939392" WEIGHT="14.416849574637876"/>
<DICH_DATA CI_END="5.866761242384134" CI_START="0.2785489255265424" EFFECT_SIZE="1.2783505154639174" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7683984142390016" LOG_CI_START="-0.5550985124470211" LOG_EFFECT_SIZE="0.10664995089599018" ORDER="35335" O_E="0.0" SE="0.7774286461508167" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="101" TOTAL_2="96" VAR="0.6043952998558918" WEIGHT="14.197303642029178"/>
<DICH_DATA CI_END="1.0780044691429063" CI_START="0.07905934454124976" EFFECT_SIZE="0.29193548387096774" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03262056133316862" LOG_CI_START="-1.1020467905913074" LOG_EFFECT_SIZE="-0.5347131146290693" ORDER="35336" O_E="0.0" SE="0.6665092192144141" STUDY_ID="STD-Lassen-2002" TOTAL_1="189" TOTAL_2="191" VAR="0.4442345392978079" WEIGHT="47.04445650671306"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1648279384631282" CI_END="1.4680542316134308" CI_START="0.17012240983302873" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4997488605766422" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.16674209921453695" LOG_CI_START="-0.7692384740077784" LOG_EFFECT_SIZE="-0.3012481873966208" METHOD="MH" MODIFIED="2017-07-26 17:44:41 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5585486151528405" P_Q="1.0" P_Z="0.20707812501547163" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1253" TOTAL_2="1264" WEIGHT="100.0" Z="1.2616407104960472">
<NAME>Pulmonary embolism</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.223110242169969" CI_START="0.009471692119371888" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.62563241861202" LOG_CI_START="-2.0235724272840576" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2017-04-20 09:04:40 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="1.5561560402548393" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="2.4216216216216213" WEIGHT="24.81377823332289"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35306" O_E="0.0" SE="0.0" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="99" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35307" O_E="0.0" SE="0.0" STUDY_ID="STD-Kujath-1993" TOTAL_1="126" TOTAL_2="127" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.2285679729069034" CI_START="0.009634234251847625" EFFECT_SIZE="0.20183908045977011" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6261933161312853" LOG_CI_START="-2.0161827982283547" LOG_EFFECT_SIZE="-0.6949947410485348" MODIFIED="2017-02-14 12:22:00 +0000" MODIFIED_BY="[Empty name]" ORDER="35308" O_E="0.0" SE="1.5521448095475698" STUDY_ID="STD-Lassen-2002" TOTAL_1="217" TOTAL_2="221" VAR="2.4091535098054617" WEIGHT="24.929616510087786"/>
<DICH_DATA CI_END="2.9746358476218573" CI_START="0.21275182024866876" EFFECT_SIZE="0.7955244755244755" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.47343380735927104" LOG_CI_START="-0.6721267155180125" LOG_EFFECT_SIZE="-0.09934645407937076" MODIFIED="2017-02-14 12:28:30 +0000" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.6729079217541591" STUDY_ID="STD-Van-Adrichem-2017" TOTAL_1="719" TOTAL_2="716" VAR="0.4528050711595015" WEIGHT="50.256605256589324"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.750425516921629" CI_END="0.7618232788932948" CI_START="0.21234705345014884" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.40220756895255233" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="31" I2="15.79701679877974" I2_Q="100.0" ID="CMP-001.10" LOG_CI_END="-0.11814576081600447" LOG_CI_START="-0.672953760946998" LOG_EFFECT_SIZE="-0.3955497608815012" METHOD="MH" MODIFIED="2017-07-26 17:44:31 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.31387713369119274" P_Q="0.0" P_Z="0.005194654960738939" Q="1.160539230933878E-31" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1469" TOTAL_2="1455" WEIGHT="100.00000000000003" Z="2.794708386462086">
<NAME>Symptomatic venous thromboembolism</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.223110242169969" CI_START="0.009471692119371888" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.62563241861202" LOG_CI_START="-2.0235724272840576" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2017-04-20 09:07:58 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="1.5561560402548393" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="2.4216216216216213" WEIGHT="7.5703062248730735"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35337" O_E="0.0" SE="0.0" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="148" TOTAL_2="152" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8796318679826531" CI_START="0.00536381927823702" EFFECT_SIZE="0.10040919106074914" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2740727996046331" LOG_CI_START="-2.270525863144566" LOG_EFFECT_SIZE="-0.9982265317699663" ORDER="35338" O_E="0.0" SE="1.4947098504654053" STUDY_ID="STD-Kock-1995" TOTAL_1="176" TOTAL_2="163" VAR="2.2341575370783144" WEIGHT="14.334825143115763"/>
<DICH_DATA CI_END="1.5119913262850933" CI_START="0.058950427579951725" EFFECT_SIZE="0.2985507246376812" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17954929979129464" LOG_CI_START="-1.2295130405274983" LOG_EFFECT_SIZE="-0.5249818703681018" ORDER="35339" O_E="0.0" SE="0.8276901936743345" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="117" TOTAL_2="109" VAR="0.6850710567046573" WEIGHT="18.790148261000432"/>
<DICH_DATA CI_END="1.3612664982421794" CI_START="0.004267231118802594" EFFECT_SIZE="0.07621573828470381" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1339431563466558" LOG_CI_START="-2.369853834548141" LOG_EFFECT_SIZE="-1.1179553391007424" ORDER="35340" O_E="0.0" SE="1.4707427464465963" STUDY_ID="STD-Lassen-2002" TOTAL_1="217" TOTAL_2="221" VAR="2.163084226225277" WEIGHT="19.774681473984174"/>
<DICH_DATA CI_END="1.7508748522529811" CI_START="0.3322587065321144" EFFECT_SIZE="0.7627210589128783" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.24325510501072414" LOG_CI_START="-0.4785236299508829" LOG_EFFECT_SIZE="-0.11763426247007938" MODIFIED="2017-06-08 13:35:22 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.4239764017788084" STUDY_ID="STD-Van-Adrichem-2017" TOTAL_1="719" TOTAL_2="716" VAR="0.1797559892653056" WEIGHT="39.53003889702657"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-26 17:40:41 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.6" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1561" TOTAL_2="1550" WEIGHT="0.0" Z="0.0">
<NAME>Mortality due to pulmonary embolism</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-19 18:10:12 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.0" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:17:44 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.0" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="99" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:18:02 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.0" STUDY_ID="STD-Kock-1995" TOTAL_1="176" TOTAL_2="163" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:19:06 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.0" STUDY_ID="STD-Kujath-1993" TOTAL_1="126" TOTAL_2="127" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:19:09 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:19:14 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="117" TOTAL_2="109" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:19:22 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.0" STUDY_ID="STD-Lassen-2002" TOTAL_1="183" TOTAL_2="188" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:19:44 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Adrichem-2017" TOTAL_1="719" TOTAL_2="716" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.15061134292296" CI_START="0.013481089304290678" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3314801945795691" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.9111901845560035" LOG_CI_START="-1.8702750143489861" LOG_EFFECT_SIZE="-0.4795424148964913" METHOD="MH" MODIFIED="2017-07-26 17:41:05 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.4991545025310382" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1561" TOTAL_2="1550" WEIGHT="99.99999999999999" Z="0.6758206880506736">
<NAME>Mortality due to other causes</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-19 18:10:38 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.0" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:27:46 +0100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.0" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="99" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:25:03 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.0" STUDY_ID="STD-Kock-1995" TOTAL_1="176" TOTAL_2="163" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:24:57 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Kujath-1993" TOTAL_1="126" TOTAL_2="127" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:24:49 +0100" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:24:46 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="117" TOTAL_2="109" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:24:39 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.0" STUDY_ID="STD-Lassen-2002" TOTAL_1="183" TOTAL_2="188" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.15061134292296" CI_START="0.013481089304290678" EFFECT_SIZE="0.3314801945795691" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9111901845560035" LOG_CI_START="-1.8702750143489861" LOG_EFFECT_SIZE="-0.4795424148964913" MODIFIED="2017-07-19 13:25:44 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="1.6338464263115806" STUDY_ID="STD-Van-Adrichem-2017" TOTAL_1="719" TOTAL_2="716" VAR="2.669454144771123" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.586868303086288" CI_END="4.861530861301182" CI_START="0.8292332212174144" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="2.007820434243224" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="63" I2="56.84770147367433" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.6867730470251053" LOG_CI_START="-0.08132330727475891" LOG_EFFECT_SIZE="0.30272486987517316" METHOD="MH" MODIFIED="2017-07-19 13:11:38 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.040908800502146625" P_Q="1.0" P_Z="0.12236175242938412" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.49139162659859753" TOTALS="YES" TOTAL_1="1595" TOTAL_2="1583" WEIGHT="100.0" Z="1.5449359676254326">
<NAME>Adverse outcomes</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1011.3174500659793" CI_START="3.597683129215768" EFFECT_SIZE="60.319148936170215" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" LOG_CI_END="3.0048875009635463" LOG_CI_START="0.5560229096228695" LOG_EFFECT_SIZE="1.7804552052932079" MODIFIED="2017-04-20 09:15:13 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="1.438475183028743" STUDY_ID="STD-Bruntink-2017" TOTAL_1="92" TOTAL_2="94" VAR="2.069210852189576" WEIGHT="7.949950966050013"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-07-19 13:11:38 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.0" STUDY_ID="STD-Jorgensen-2002" TOTAL_1="99" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="191.15778137489508" CI_START="0.5753083192695053" EFFECT_SIZE="10.486880466472304" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.281391981347438" LOG_CI_START="-0.2400993457959566" LOG_EFFECT_SIZE="1.0206463177757406" MODIFIED="2017-04-15 11:47:43 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="1.4811364871473998" STUDY_ID="STD-Kock-1995" TOTAL_1="176" TOTAL_2="163" VAR="2.1937652935593395" WEIGHT="7.58118231269506"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-15 11:48:09 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.0" STUDY_ID="STD-Kujath-1993" TOTAL_1="126" TOTAL_2="127" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.94314652827659" CI_START="0.11674769750302855" EFFECT_SIZE="2.9381443298969074" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.868897927313532" LOG_CI_START="-0.932751675829001" LOG_EFFECT_SIZE="0.4680731257422654" MODIFIED="2017-07-18 13:29:11 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.645702845275126" STUDY_ID="STD-Lapidus-2007a" TOTAL_1="49" TOTAL_2="47" VAR="2.7083378549466453" WEIGHT="6.361995370959068"/>
<DICH_DATA CI_END="15.070076081301924" CI_START="0.05751963051872835" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.178115444856516" LOG_CI_START="-1.2401839123364538" LOG_EFFECT_SIZE="-0.03103423373996879" MODIFIED="2017-07-18 13:29:09 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.4205210131900308" STUDY_ID="STD-Lapidus-2007b" TOTAL_1="117" TOTAL_2="109" VAR="2.0178799489144317" WEIGHT="8.112579104057362"/>
<DICH_DATA CI_END="2.715432735562656" CI_START="0.5973773699658004" EFFECT_SIZE="1.2736318407960199" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.43383904928081773" LOG_CI_START="-0.22375123349809636" LOG_EFFECT_SIZE="0.10504390789136069" MODIFIED="2017-07-18 13:20:02 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.38627178722873184" STUDY_ID="STD-Lassen-2002" TOTAL_1="217" TOTAL_2="221" VAR="0.1492058936088787" WEIGHT="31.777619344075813"/>
<DICH_DATA CI_END="1.712111259902829" CI_START="0.7721052784851221" EFFECT_SIZE="1.149752208575738" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="49" LOG_CI_END="0.23353198346719845" LOG_CI_START="-0.11232347848827334" LOG_EFFECT_SIZE="0.06060425248946255" MODIFIED="2017-04-15 11:51:09 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.20315721036479176" STUDY_ID="STD-Van-Adrichem-2017" TOTAL_1="719" TOTAL_2="716" VAR="0.04127285212320425" WEIGHT="38.216672902162685"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvIAAAOVCAYAAAALHQQaAACAAElEQVR42uydD2SW3///v0wyk4nJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-07-28 10:11:18 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias domain, presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-07-28 10:11:19 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias domain for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVYAAAJFCAIAAAAJZ0h8AAAcFklEQVR42u3dsY4cx9WG4QUMGA42
YMAr8DVsZCwc2ZHvyQw3IGCGvAvDlyCYUkgzcmZYXgoSAwWUnUmy0P/Q+8MY78709HT3qTmn6/mw
EKjh7mFtd9Vbp6qrz3d1RUSdayCiLgUBRBAAAUQQQEQQQEQQQEQQQEQQQEQQQEQQQEQQQDShMzly
CgHUZzea8iFBAG2wD83+W4IAIoIA2lY6oFNBAHU9/i0BIIAgAAIggCCAIIB660zGPwQQEQQQEQRQ
j53JGWEIoD570v4fdCoIoK4RgAIQQBCgX0EA9UoBnQoCiAgCiAgCqIf8n1clBBARBBARBFDXnckq
AAKo2x2B8U8IAggCCAKoAwroVBBAnW4B2A6AACKCACKCACKCACKCACKCAOqiMykcBgHUZ0869geC
AIIAggCCAIIA6mEvQKeCACKCACKCAOpwO8BGAARQ1+MfBSCAIAACIID67EyeCEAAEUEAEUEAdbwQ
0K8ggPrqSS4CBBAEtMgvXG0IoF4ocLB/6rQQQAU2Apb3q/EI+i0EEBEEUE9LDN0VAqjSWmD18W8J
AAFUYKJed5RCAARQPQSsOFAhAAKoawQ82gLQXSGAClBAp4IAIoIAohW7qTPCEEAdDtS4Zw0EAbT+
RkDoFkP0vwUBlHRGhQAIgIC+bsmUD/ukgO4KAf2m08nvlE07CCDwIgigLlPfoHohQ0wlAoKAMuO/
0ByrI0EA9YsAczUEUO9ZQDO+6CEQ0MuNsQoYuBVCAJVLXiAAAqj3XH3dfrUfSneFgE5HlItgOwAC
usuovRtHEAABZbJfEzUEUL8IsGkHARRFgaIPBfUrCKAemQUBEEB9d6aAvQBPBCCgr7m01mOw6Lbp
nxBANbAFARBAlgDhpwMJAqyr+1oOOB0IAZ2m1rWmQb0IAqhrBKAABFDUcKp4Onj1vQCrAAjocQtA
vx8cOoIA0kchAAKoUgqz7iiFAAigSnN1xNuN1kQQQF0jgCCAIIAgoMt1da0Dgus2mKEYBPQ+oxJB
AAS4Gp4IQIB+X3DxErEashCAgE43AnouH6p/QgBJ1wkCqBQFVq8diCwQ0PVaoOjiZZXGyy8gQFI9
eFMw6GrYZYQACFi/tau3PGKgHgzV4XCAAPNej8OpAbYggLobqJJqCKBKmUWheS+oEsFQ0LsRAqhf
eK3+DqK3GyEgaXdvY8tRzqEAAiCAeuz0EAAB1u29d/poz+Juxz8EZO/rEQ8FVkeA9/kggMKzgJ7n
PWclIYDkRI18iuwFUMapr8oNauYjsHrkiBMHEEBJU99CuwzNrrMnAhDQCwLi5r02ViKF2gwBtOZc
nb/TF31674AwBHSaXxSy/TJXQwBFUaDzA8IEAQUWAnr8wKcIAqTrRcsHupUQQFkQED3v6UUQQF1n
AREtbH86EAJos6vfohR4Gjn03KG9AAKXNWfs5AMVAiCg3yVGoU4ffVy68+0MCEg9RReaUWtlLmoc
QIBEYP3xbzhBAMkvYpcAna/bIaDHETuUre2z4nWY8iFBwAZz9eoVvtLuBVTcv4AACKi30Oh5Xq2S
uUAABEiD18RWuf0LCJBGQq2e5kKY97rEVnSx9uRLAAgw78VGLnGcKe5BRpWlHAQU2A6oVZB7xX+r
wVkG9ZQhIPv4LzfvNcgCOr+DEAABGee9wRbmoauRn2LuljmkzHCCLQgwh3QNxEKLFwigMjNqUPLS
7RZmg8wFAvqd8SLOrtXy/KmCgEKGpRCQegkw/mEnCKi4hemJAGXvmrWygLrZHARQX3sBxn/0zggE
UNfYWgsuDMUggKImvZ6Tagig7EM0emutFgKC3muolV9AAIVsMSR/5UYRcQioN6LSznvtr0b+xQsE
ULquad7bBrYgAALyznuFCp+3t1q3F0Abz1GjDwjXylwggNZP2iN6Z4kjsXVzohJAh4Dek4sS7wgU
yrbK7blAAAQUKL8R6lbmoSAEFFgLlIjccmWkh0CAubrfq+E6QwAEdJS5OCUBARAQsmIfggv7VKwa
ZCFAvcyoJV65GZmxK7aZszAlyi+iK/zlPx0YPUoPXg3OwrRZBFRcXbffaIQAmtR1eP6MkKuoZzEE
ECVdvLRELQTQojkEAlZfvCSfoiGg1/sRsBCo+yS8GQIGR4MobRbggoQ+wuj5BWcIoLyZS+MUo8+S
ZBBQZlytHnn1nlroXIA8DgIqrX47Px0YMVdH27cWogAEFEDAULOwR/I2R9u32gugvhAw1HTpVYYA
AgpQoPOSIR7dQQDppmU8ixmKUci6utJ8oryXLIAyU8CT8IvcPlkALZpOlfou5FOkiDgVmJ2iS4YU
anObekQWArRxBJTOXBpUUoQAypL6Ftpdb4yAPikAAd2l6xvYHOk5J4IACAiZlIJOxda61E4H0saz
gOhT8UHraoIAqW+BA8Jt1tXRZxk6fPsAAqjAujpiWRT69N7RIOqdAkVrHJTILyCgx4WACsJDqecj
EEBJZ6fSQIy4OCxbIKAvBHAoGMkvPBSkLVOgdJ1fSwwI6H0joMPXV46NVSXJIIAM1K5PHEAArZxi
JB+onghAQNcDdSjy+hoEjFxqCwFKN5wKtXkIeCjY4HRglc1XCOgLAdEUKLe1zgQNArrLAjwUrLhi
h4B+9wLKvXgfMZwqvsxTpeQpBFCBdfX+H7w6DQGUcXYqutGozRBQaV41nLQZAjqiwEh/ytk1Q9+6
2/8nKnLcXgAtSqrXytuLugkRBEDAakv36ImaBlYiFDRQS/hqF73OQ8CzBgigfplVol85ggUBxqrT
gSEIsBdAcvUC6XpR1yYIoKQIKFeJYIjZHA11bYIASkqBBkbd5eoFOBdA6VLfQdUggoBCE7WSIdEz
qs1RCICAkGYXfcFZFkAbR4B+71JAQLG9gFCXq0LTtXPNEED9YqscXAoZN0EARQ3UihbgQcEzP8uA
gAIjqkrZ7LgBFn2WoRkQIYAuP5wKYavuXgAEUHcIiMsyoo0P2uy8WgjQCh0o+YxaccVOENBpfpG/
vj0KQACFI2BY7/XYxv58si0I6Gsh4JWbNslFh8VUIaC7vLdiQW4IgAAIKNbsWrZfEc1WPpT6okDL
GTX/XoDyoZS3AzXzFCyBAIKATpOLQoU9IAACqAYCmqVFmfcvoh+RQkB3a4FBKc6C+xeyAOooXS83
79m/gADpeuHpOvnjxuiXsiEAAsyog1ebIKCjvYASG2BFi5E4HQgBXWfUhTp9xXTd6UCCgHpXI4hZ
9gIoUQdqs8QogS2CgN4nq+TYarDLwFAMAlDA7x7yD3EWpqS907zX4Do7GkRJR+lmnHkgAAIoFwKa
FSYtkRBBAHVHgZYnGjt/uxECelwIhO6xQ4DO5oKmnqvLVfuPLsLV4VwNAb3n6u5RuetsIUC6Zr/X
2XYgJR2oReFS7mpAAJn3ui4iPtTZzYEACOgaAW2SuMwrLwjI3oeGOmfXg+Y9m6MQ0O9cXatwWNy8
ZwsTAiDAPZLHQQAEJE7XqSjEIaBGXm1dXWuuhgDKPjutiIC67wLEDVQIoI7yi7jlbrP3jguZrEJA
j4vJuo8DMkcebLtCQInxX6VrFl0OFK3OtOL0AAEQQJXItXrfgAAIyD6jDjVfE6qyeIGA1MOp1viP
G06rRy7n/wsBFDWjMv/sfHqAAAvUoVsEEARAQNd7AUOdk/wQQDUoUPRSlN52tRdAi3oPt8Ih+HTg
EPn2gb2Ajsaqa1IIAYUi615ydagNPHEAAZQOAZKLDSwx9m+lhQAKLAobeh4u/5tCUAsBfe0FRBfk
HpkGU0WuezoQAqQAebOAg59ElCSpUpAv4t6tji0IsBcwQED0pZYFUC4KtIRLXBHxQuXJM48yCKix
EeAe1VoWhWYB63YM3auv7g4uzXZGqjzTgQAKTF5KRK61+IKATodTiXmv3LZIxKPBBtnWutiCgF4S
1Ogn4XXdBOomWR4KQkCu4YQCDe5gFFmMOh0oYo5KHjlil6HcuUMI6GsvYPAasrQFAuQXQ50DdkUR
UG+ycSH6RMCw3gHeiNS38e56HF8yNxgCCqyouei1vOBBAzUtBSCgQI66+i3fv/cucpvIaTdHIaBG
1yxQcyJmIVD0LMOgZAj1g4CWmUto5K6XQkZd8qk1/3AqaihW8RHpuuXJIUB+0a+nYKGB+vR3V0GY
0g2nioZi0ddZEXFaLUftdjhVXHBBAK08V1PRZVGoVZmqQRDQaeZS5QCPh4KUkQKlT9oW2hkpBm5D
Lvl0WnHfvkROVHFnxOlAypv6WhmVO9EIARCQ/ZiNqscQYC3goWCLEVVoIQABvfRLhT1KL4vWPR2o
fGi/CBjSvyk41CwZUvRcgIUABCSaQza24MoPcVYiPVLADQJxCwEqM5H2XJC7ZX5hIUAWAiGXpdMr
YIQk7JSh7KeiV3V1YEFA3k65vx8e2p/WxVbQuaDVI8chYL+R+R9hQEBqBIT20Yh+ubrpbVDk0KV1
g6ux4q8AAdmzgKCR38DrOj8C4s4yQAClQ0Dc5kLpLKDZHYQAkgVAgL0AmpWaxlXjTN7moicOHoVK
/pYXBCCOu68P6AREEEBEEEBEEEBEEEBEEEBhV5yorSAgEQJEFjlPZAiAAJEhAAIgQGQIIAgQGQII
AkSGAIIAkSGALnWbP/748e7+7vbd7bPPn119dnX95vrm7c2LL198+8O3aSP/9NPH7767+/Dh9v37
Z//4x9X9/fU339x8/Pjip5/ytvnHjx/v7+7e3d5+/uzZZ1dXb66v397cfPnixQ/fftvVHYSAXAh4
/fXr5188393dp1+7u/7qq1cJI//rX6/fv3++G/lPv3ZE+Oc/M7b569evv3j+/FDgqx0Rvnr1qp87
CAGJELDD+cEbvP+1+55UkXdT/cHBv/+1+55Ubd5N9acCX+2+p5M7CAFZELBj/Ml7/PB1jPftI+/m
/5Pj/+HrWC7Qvs27+X9a4KtjucCW7mAKBAQVbxwPdfJvD1byP9jCY9927Nc5+OFujXcsxzuY9X34
/sPFI+/W//v5/5//fPXrX1/94hefvn73u6u//OXxiuDf/758m3fr/2P5/8EVwfcfPmz4DiZCwIqb
ohN/fPyKjANlep3v6Qi4u7+beI9HUr7Gkb/77m5/kP/yl58uxZ/+dPXHP376w69+NWk50LjN93d3
5wQ+vBzYzB3MjoD9Kpcjw/KYbcPItw2T6zqOI2C8DudZn9++uz1wOx906DbfvL25eOQPH24P5vx/
+9un2D//+ePPv/nm8m1+d3t7FgLe3txs+A4WQMDJETji33rut81AwLlT/chfPTzjmX6br99cXzzy
w/O/R19//evVb37zKfYf/vD4r+7vL9/mh+d/07/eXF9v+A5m3ws4+efxD5dM4BMbsCICDt/gfT25
0xePfDAF+O1vP4X8/e8PbwpevM1Ph8zzE4GvNnwHaywE4hBw8hdviYDNZAE/+9mnwH//+4HxLwuQ
BeRCwFkr9rMQMONhxJb2Ao592QuwF7ACAqZsECxHwPiojkDABp4IPHw9aPoBIU8EPBGYtBewP/gn
MmIiAqY/2J94LmAeAjZwLmAcAc4FOBdAJ26G04Ft2ux0IAQkRcDgHYFWbfaOAAQkRcAD7w/vAP8n
x3v5/mXCyP95U/DZ8TcFM7Z5lwscezqw+/z9y5f93EEIyIWA4fg74QfXeEkiH6sXcHD9n6TNx+oF
HFz/b/gOQkA6BIgscsvIEAABIkMABECAyBBAECAyBBAEiAwBBAEiQwDF3QwizsKyAJFFlgVAgMgi
QwAEiCwyBECAyCJDAASILDIEQIDIIkNA1wio6Cxc0aU3rs21fJYhIBcCKjoLV3TpjWtzOZ9lCEiE
gIo1ZypW4Ilrc8UaShCQBQEVK89VrMMX1+aKlRRbIKAiX6Y7C5/lQTxyQSrWn61YjTeuzRV9liHg
dINnVCI/aVi6mSr0FWvyx7W5os/yBRBwzCxgxAVg/KfmzcnHfnyk8SuO9s140VR05olrc0Wf5dYI
OMsdeImn8DDXkuiCCKjoSFfRny+uzRV9lrMgICIDnxFz4s9Oj3PWXkBFX9qKLr1xba7os1wGAU/f
eR75qWMuYFN+/IIIkAVsMgtI7rMciIDlm2cz5vaT3Jn+48M0Z+FzHcftBXS4F5DZZzkvAqbbBzfb
tJ/Hr+kI8ERgY08ESvgsxy4Eztqcf/QNE58ITFkInPXjI2uHs4KPV2tyLqCHcwElfJYb7QV0cppg
+a/mdGD1NjsduFrisO0Dy94R2HCbvSNASxOcis7CFV1649pczmcZAtKtcSo6C1d06Y1rcy2fZQjY
zjaHyCJDAASILDIEQIDIIkMABIgsMgRAgMgiQwAEiCwyBKRCABFnYVmAyCLLAiBAZJEhAAJEFhkC
IEBkkSEAAkQWGQIgQGSRIaBrBMR56cY53nLprdtmCMiFgDgv3TjHWy69pdsMAYkQEFcZJq6ajQo8
1dsMAVkQEFcfLq6mnTp81dtcGAHTrTvmLbpGKgtP/zBDBeE4x1suvdXbvCkEnPsrnCz1v8RKJJWP
QJzjLZfe6m3eDgKmz8wTf3xY4CY0I78YIh1j4hxvufRWb/NGEHDWWB33I56YZUyxQhq5qo194+Ic
b7n0Vm/zFhAww/lr/MdPImCeG/rJmxHnHhvneMult3qbyyNgXsY+sliYsh04HLIwO2+0J5idVnG8
5dJbvc3b3As4KwsYzrQAP3tun/xh+zXqcsdbLr3V27zNJwIZ9gJmIKDZTvWKjrdcequ3eVMIOLgh
N++JwFlrh+kfjv9zzZ5Xr+h4y6W3eptrI6CunA68bJudDoSApAgYvCPQqs3eEYCApAgYIr104xxv
ufSWbjME5ELAEOmlG+d4y6W3bpshIB0CRBa5ZWQIgACRIQACIEBkCCAIEBkCCAJEhgCCAJEhgOJu
BhFnYVmAyCLLAiBAZJEhAAJEFhkCIEBkkSEAAkQWGQIgQGSRIaBrBMT50nIWrt5mzsLbR0CcLy1n
4ept5iy8fQTE1ZxRNah6m1UN2j4C4irPqR1Yvc1d1w48y0F4op/nlN+3cQXhOF9azsLV29x7BeGF
DsLzELDEWXiej0CcLy1n4ept7t1HYLZr0KOpeP9///vfkSG6xFx8xodxvrSchau3uXc3oYUOwsf+
Ns5NaB4C4nxpOQtXb3PvnoILHYSnA2IiAk46Cx/7ZPxfjPOl5Sxcvc29OwvPdhB++qb0EgQMwc7C
cb60nIWrt1kWMGcvYMbfLnzuELQXsNyXlrNw9TbbC7g6mdWPGwevuxBo80RgRV9azsLV2+yJwAkH
4fGFwPj3z1gItDkXsKIvLWfh6m3mLLyIF4Ua6XSgNjsduP3xP3hHQJu9I9C5LuVLy1m4eps5C3eB
gCHSl5azcPU2cxa2YSGyyCtHhgAIEBkCIAACRIYAggCRIYAgQGQIIAgQGQIo7mYQcRaWBYgssiwA
AkQWGQIgQGSRIQACRBYZAiBAZJEhAAJEFhkCukZARWfhWl66IkNAXgRUdBYu56UrMgQkRUDFqkEV
6+SIDAEZEVCxdmDFankiXxIBC/+h6TW5z4o5uy7wxAOYUxpc0Vm4opeuyLURsHrMaHeA6Q2u6Cxc
0UtX5KQIODjBDk+c+U7aBIx85xRD8dkIWO4jUNFZuKKXrsgZEXBsyI17BI1823CmcdBCBEzxHTp5
ESo6C1f00hU5+0JgiSngdK/hiRiah4B5mxcVnYUreumKnH0hsDoCJi4E1kXA+B7hZpyFK3rpilxp
IbAWAqYAaF57Tu4LbNtZuKKXrsipEfAoC5i9F3Aymzg5h6+CgLOygIrOwhW9dEW+PAIOPks/tr1/
1hOB8Q+PjcaDSftZhwWOhT0rC6joLFzRS1fkCyOgzdP+5HI6cEpkZ/jaRIaAXL+adwT25SR/m8je
EchFt4rOwuW8dEWGgNQJTkVn4VpeuiJDwDbXOCKLDAEQILLIEAABIosMARAgssgQAAEiiwwBECCy
yBCQCgFEnIVlASKLLAuAAJFFhgAIEFlkCIAAkUWGAAgQWWQIgACRRYaArhHAWXhf/H+jI0NALgRw
Ft4X/98GkSEgEQJUDdqX2j5tIkNAFgSoHfhoxlPhr0HkgbPw6s7C0x2THq2lOQvvr3jV+W0QuR4C
Vo8Z4Sw8DwGchfel2n+byIkQsCVn4YMtP3kROAvvi+dPm8hZELA9Z+HxjICz8MnInP/aRM64ENiA
s/A8T0HOwv/zIf/fJpEzLgQ24Cw8DwGchc3VA2fhgbMwZ2Er9p73AjbjLDxjL4CzsH37gbPwsAln
4XlPBDgLe3o/cBaOPkGQ/FdzOnBfzvC1iQwBuX417wjsy0n+NpG9I5CLbpyFH81+/H+jI0NAugSH
s/CjlTD/39DIELCdNY7IIkMABIgsMgRAgMgiQwAEiCwyBECAyCJDAASILDIEpEIAEWdhWYDIIssC
IEBkkSEAAkQWGQIgQGSRIQACRBYZAiBAZJEhoGsExPnS8v8VGQKyIyDOl5b/r8gQkB0BcZVh1PYR
GQKyIyCuPpwKfyLXQEAeEi2xGx5OmZc0rhLL/1dkCJjfjIUWZtN9BOJqxfP/Fbk8Alafk0+W+g8d
7Y0dY/j/ilwbARFz8knDn/YIiPON4/8r8nYWAjOMupY4ji/xGh0mWxj+/4dh7rH8f0XezkJghufX
Mf+ybAhonAXw/xW59kJg+k/NizkssxueTpYL7gXw/xW5GAJOTuOhm/YL7YbzPBHg/ytyagRM9B1e
5YnAyGhffelxwWe//H9FHpwOTCWnA0V2OhACDss7AiK3jwwBiRAwRPrS8v8VGQIKIGCI9KXl/ysy
BBRAgMgit4wMARAgMgRAAASIDAEEASJDAEGAyBBAECAyBFDczSDiLCwLEFlkWQAEiCwyBECAyCJD
AASILDIEQIDIIkMABIgsMgR0jYCKjrc/fvx4f3f37vb282fPPru6enN9/fbm5ssXL374lv8vZ2E6
5zZXdLz9+vXrL54/P1jGYkeEr17x/+UsTNNuRsWaM7up/mQ9q933dHI1VA2i+QioWHluN/9PLGx7
LBdQ4e+ykSchYLpJxio7E8u/f5VROt0v+Ni3JakgHBd5t/4/lv8fXBF8/0Gd35oVhNdFwNNy4Esi
RyDgXMuAVYhWsQr9/d3dOYEPLwdU+79g5DMWAuMD4CzT3oMIeOoUsP+/I0Pu2D83pWFrOQufi7PN
eNG8u709CwFvb3j+lHUTWtG09+CoPvizT+Mc/MPI354VfAYCVly8VHSke3j+N/3rzTXnv7KegtMd
uKY7bS40Alsl4LDMVnRFBFT0pX3a/Z6fCMz/t7Kz8EgCP920d7rP70IETG9YEgTIAszVQ3Jn4ZEE
PnMWcO54njLOTyJghq2ovQAr9iG/s/Cxrj8xCzg2VGZ4B6/oJrzEWXhFBHgiYN9+yO8sfCyxn71t
NuIdPPEh3LmPKmavVqafC5iHAOcCPL0fOAt3IqcDt3o1OAvTIgQM3hGofzW8I0CLEDDUdLzd5QLH
ng7sPn//kv8vZ2GafJuHmo63x+oFHFz/b/5qcBamRbdZZJFbRoYACBAZAiAAAkSGAIIAkSGAIEBk
CCAIEBkCKO5mEHEWJqJMc5ILQQQBRAQBRAQBRAQBRAQBRAQBRLRxBBBRt/o/KeUD98SR8KgAAAAA
SUVORK5CYII=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2017-06-08 19:33:23 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2017-07-28 10:19:06 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-06-21 15:00:58 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-06-20 15:10:13 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-06-21 15:00:58 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="66">
<TR>
<TD COLSPAN="2">
<P>Search run on Wed Apr 19 2017</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Thrombosis</P>
</TD>
<TD ALIGN="RIGHT">
<P>1267</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Thromboembolism</P>
</TD>
<TD ALIGN="RIGHT">
<P>921</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Venous Thromboembolism</P>
</TD>
<TD ALIGN="RIGHT">
<P>258</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Venous Thrombosis EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>2041</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>(thrombus* or thrombopro* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol* or microembol*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>19731</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Pulmonary Embolism EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>748</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>(PE or DVT or VTE):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>5178</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>((vein* or ven*) near thromb*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>6943</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>(blood near3 clot*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>3178</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>(pulmonary near3 clot*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>(lung near3 clot*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11</P>
</TD>
<TD ALIGN="RIGHT">
<P>25606</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Immobilization EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>630</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Mobility Limitation EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>255</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Splints EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>363</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Orthopedic Fixation Devices</P>
</TD>
<TD ALIGN="RIGHT">
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Casts, Surgical</P>
</TD>
<TD ALIGN="RIGHT">
<P>390</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Orthotic Devices</P>
</TD>
<TD ALIGN="RIGHT">
<P>466</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Foot Orthoses</P>
</TD>
<TD ALIGN="RIGHT">
<P>79</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>immobili*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>1885</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>brace*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>894</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>splint*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>1350</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>plaster*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>738</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>cast*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>3420</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>boot:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>132</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>stirrup:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>29</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>bracing:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>290</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>aircast:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>53</P>
</TD>
</TR>
<TR>
<TD>
<P>#29</P>
</TD>
<TD>
<P>#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28</P>
</TD>
<TD ALIGN="RIGHT">
<P>8235</P>
</TD>
</TR>
<TR>
<TD>
<P>#30</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Lower Extremity EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>5947</P>
</TD>
</TR>
<TR>
<TD>
<P>#31</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Leg Injuries EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>2736</P>
</TD>
</TR>
<TR>
<TD>
<P>#32</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Achilles Tendon</P>
</TD>
<TD ALIGN="RIGHT">
<P>240</P>
</TD>
</TR>
<TR>
<TD>
<P>#33</P>
</TD>
<TD>
<P>leg:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>12176</P>
</TD>
</TR>
<TR>
<TD>
<P>#34</P>
</TD>
<TD>
<P>(lower extremity):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>2916</P>
</TD>
</TR>
<TR>
<TD>
<P>#35</P>
</TD>
<TD>
<P>(lower limb):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>3036</P>
</TD>
</TR>
<TR>
<TD>
<P>#36</P>
</TD>
<TD>
<P>ankle:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>5156</P>
</TD>
</TR>
<TR>
<TD>
<P>#37</P>
</TD>
<TD>
<P>achilles:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>604</P>
</TD>
</TR>
<TR>
<TD>
<P>#38</P>
</TD>
<TD>
<P>#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37</P>
</TD>
<TD ALIGN="RIGHT">
<P>23101</P>
</TD>
</TR>
<TR>
<TD>
<P>#39</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Heparin, Low-Molecular-Weight EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>1522</P>
</TD>
</TR>
<TR>
<TD>
<P>#40</P>
</TD>
<TD>
<P>*parin*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>58379</P>
</TD>
</TR>
<TR>
<TD>
<P>#41</P>
</TD>
<TD>
<P>LMWH:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>866</P>
</TD>
</TR>
<TR>
<TD>
<P>#42</P>
</TD>
<TD>
<P>LMH:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>#43</P>
</TD>
<TD>
<P>(Clexane or klexane or lovenox):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>46</P>
</TD>
</TR>
<TR>
<TD>
<P>#44</P>
</TD>
<TD>
<P>(Fragmin or normiflo or clivarin* or danaproid or danaparoid ):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>245</P>
</TD>
</TR>
<TR>
<TD>
<P>#45</P>
</TD>
<TD>
<P>(antixarin or Zibor):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>#46</P>
</TD>
<TD>
<P>(cy 222):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>#47</P>
</TD>
<TD>
<P>(embolex or monoembolex or Mono-embolex):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>24</P>
</TD>
</TR>
<TR>
<TD>
<P>#48</P>
</TD>
<TD>
<P>Kabi-2165:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>39</P>
</TD>
</TR>
<TR>
<TD>
<P>#49</P>
</TD>
<TD>
<P>(pk-10169 or pk10169):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>#50</P>
</TD>
<TD>
<P>(cy-216 or cy216):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>46</P>
</TD>
</TR>
<TR>
<TD>
<P>#51</P>
</TD>
<TD>
<P>(Boxol or Liquemine):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>#52</P>
</TD>
<TD>
<P>fr-860:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>#53</P>
</TD>
<TD>
<P>(kb-101 or kb101):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>#54</P>
</TD>
<TD>
<P>(fluxum or lohepa or lowhepa ):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>#55</P>
</TD>
<TD>
<P>(op 2123 or op2123):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>#56</P>
</TD>
<TD>
<P>AVE5026 :TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>#57</P>
</TD>
<TD>
<P>M118:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>#58</P>
</TD>
<TD>
<P>(RO-14 or RO14):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>#59</P>
</TD>
<TD>
<P>#39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58</P>
</TD>
<TD ALIGN="RIGHT">
<P>58468</P>
</TD>
</TR>
<TR>
<TD>
<P>#60</P>
</TD>
<TD>
<P>#38 AND #59</P>
</TD>
<TD ALIGN="RIGHT">
<P>1865</P>
</TD>
</TR>
<TR>
<TD>
<P>#61</P>
</TD>
<TD>
<P>#12 AND #38</P>
</TD>
<TD ALIGN="RIGHT">
<P>1551</P>
</TD>
</TR>
<TR>
<TD>
<P>#62</P>
</TD>
<TD>
<P>#12 AND #29</P>
</TD>
<TD ALIGN="RIGHT">
<P>276</P>
</TD>
</TR>
<TR>
<TD>
<P>#63</P>
</TD>
<TD>
<P>#29 AND #59</P>
</TD>
<TD ALIGN="RIGHT">
<P>655</P>
</TD>
</TR>
<TR>
<TD>
<P>#64</P>
</TD>
<TD>
<P>#60 OR #61 OR #62 OR #63</P>
</TD>
<TD ALIGN="RIGHT">
<P>3438</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-07-28 10:19:06 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2017-07-28 10:11:38 +0100" MODIFIED_BY="[Empty name]">Trials registers searches</TITLE>
<APPENDIX_BODY MODIFIED="2017-07-28 10:19:06 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Clinicaltrials.gov</HEADING>
<P>73 studies found for: heparin AND leg</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">WHO ICTRP</HEADING>
<P>16 records for 14 trials found for: heparin AND leg</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ISRCTN</HEADING>
<P>20 results found for: heparin AND leg</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;8 studies included in quantitative synthesis (meta-analysis)&lt;/span&gt;&lt;/p&gt;" WIDTH="142">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies included in previous version of review&lt;/p&gt;" WIDTH="170"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 new studies (5 records) included in review&lt;/p&gt;" WIDTH="169">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="166">
<FLOWCHARTBOX TEXT="&lt;p&gt;448 records screened by review authors&lt;/p&gt;" WIDTH="172">
<FLOWCHARTBOX TEXT="&lt;p&gt;1279 records screened by Information Specialist&lt;/p&gt;" WIDTH="178">
<FLOWCHARTBOX TEXT="&lt;p&gt;1279 new records since previous version of review after duplicates removed&lt;/p&gt;" WIDTH="175">
<FLOWCHARTBOX TEXT="&lt;p&gt;CENTRAL: 3438 records&lt;/p&gt;&lt;p&gt;Clinicaltrials.gov: 73 records&lt;/p&gt;&lt;p&gt;WHO: 16 records for 14 trials&lt;/p&gt;&lt;p&gt;ISRCTN: 20 records&lt;/p&gt;" WIDTH="186"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;8 records identified from Cochrane Vascular Specialised Register&lt;/p&gt;" WIDTH="158"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;831 records not relevant&lt;/p&gt;" WIDTH="165"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;432 records not relevant&lt;/p&gt;" WIDTH="177"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9 additional studies (10 citations) excluded with reasons&lt;/p&gt;&lt;p&gt;1 record added to previously excluded study&lt;/p&gt;" WIDTH="178"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>